{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T12:28:51Z","timestamp":1784204931904,"version":"3.55.0"},"reference-count":363,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T00:00:00Z","timestamp":1723680000000},"content-version":"am","delay-in-days":349,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI-169296"],"award-info":[{"award-number":["AI-169296"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HL-70227"],"award-info":[{"award-number":["HL-70227"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart Lung and Blood Institute","doi-asserted-by":"publisher","award":["HL161818"],"award-info":[{"award-number":["HL161818"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.xphs.2023.05.014","type":"journal-article","created":{"date-parts":[[2023,5,21]],"date-time":"2023-05-21T09:39:34Z","timestamp":1684661974000},"page":"2347-2370","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Immunogenicity of Therapeutic Biological Modalities - Lessons from Hemophilia A Therapies"],"prefix":"10.1016","volume":"112","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8998-0145","authenticated-orcid":false,"given":"Nhan H.","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole L.","family":"Jarvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sathy V.","family":"Balu-Iyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.xphs.2023.05.014_bib0001","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1056\/NEJMoa1614062","article-title":"Lipid-reduction variability and antidrug-antibody formation with bococizumab","volume":"376","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.xphs.2023.05.014_bib0002","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1111\/jth.12634","article-title":"Recombinant factor VIIa analog in the management of hemophilia with inhibitors: results from a multicenter, randomized, controlled trial of vatreptacog alfa","volume":"12","author":"Lentz","year":"2014","journal-title":"J Thromb Haemost"},{"issue":"11","key":"10.1016\/j.xphs.2023.05.014_bib0003","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1111\/jth.13141","article-title":"Changes in the amino acid sequence of the recombinant human factor VIIa analog, vatreptacog alfa, are associated with clinical immunogenicity","volume":"13","author":"Mahlangu","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"6","key":"10.1016\/j.xphs.2023.05.014_bib0004","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1111\/hae.12994","article-title":"TRUST trial: BAY 86-6150 use in haemophilia with inhibitors and assessment for immunogenicity","volume":"22","author":"Mahlangu","year":"2016","journal-title":"Haemophilia"},{"key":"10.1016\/j.xphs.2023.05.014_bib0005","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2147\/JBM.S6885","article-title":"Treatment of hemophilia: a review of current advances and ongoing issues","volume":"1","author":"Coppola","year":"2010","journal-title":"J Blood Med"},{"issue":"2","key":"10.1016\/j.xphs.2023.05.014_bib0006","first-page":"178","article-title":"The modern treatment of haemophilia: a narrative review","volume":"11","author":"Franchini","year":"2013","journal-title":"Blood Transfus"},{"issue":"3","key":"10.1016\/j.xphs.2023.05.014_bib0007","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1055\/s-2002-32667","article-title":"Hemophilia A\u2013from basic science to clinical practice","volume":"28","author":"Klinge","year":"2002","journal-title":"Semin Thromb Hemost"},{"issue":"2","key":"10.1016\/j.xphs.2023.05.014_bib0008","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ejmhg.2010.10.005","article-title":"Molecular genetics of hemophilia A: clinical perspectives","volume":"11","author":"Tantawy","year":"2010","journal-title":"Egypt J Med Hum Genet"},{"issue":"3","key":"10.1016\/j.xphs.2023.05.014_bib0009","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1055\/s-0037-1615621","article-title":"Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis","volume":"85","author":"White","year":"2001","journal-title":"Thromb Haemost"},{"issue":"4","key":"10.1016\/j.xphs.2023.05.014_bib0010","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1055\/s-0037-1615061","article-title":"Factor VIII inhibitors in mild and moderate-severity haemophilia A. UK Haemophilia Centre Directors Organisation","volume":"79","author":"Hay","year":"1998","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.xphs.2023.05.014_bib0011","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/978-1-4615-1277-6_6","article-title":"Factor VIII inhibitors","volume":"489","author":"Lollar","year":"2001","journal-title":"Adv Exp Med Biol"},{"issue":"10","key":"10.1016\/j.xphs.2023.05.014_bib0012","first-page":"15","article-title":"Hemophilia. Strategies for the treatment of inhibitor patients","volume":"85","author":"Ingerslev","year":"2000","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.xphs.2023.05.014_bib0013","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1182\/asheducation-2016.1.657","article-title":"Hemophilia and inhibitors: current treatment options and potential new therapeutic approaches","volume":"2016","author":"Meeks","year":"2016","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.xphs.2023.05.014_bib0014","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.omtn.2020.03.015","article-title":"Treatment of hemophilia A using factor VIII messenger RNA lipid nanoparticles","volume":"20","author":"Chen","year":"2020","journal-title":"Mol Ther Nucleic Acids"},{"issue":"4","key":"10.1016\/j.xphs.2023.05.014_bib0015","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.3324\/haematol.2018.210583","article-title":"Correction of bleeding in experimental severe hemophilia A by systemic delivery of factor VIII-encoding mRNA","volume":"105","author":"Russick","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.xphs.2023.05.014_bib0016","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2147\/JBM.S103796","article-title":"Many factor VIII products available in the treatment of hemophilia A: an embarrassment of riches?","volume":"8","author":"Lieuw","year":"2017","journal-title":"J Blood Med"},{"issue":"8","key":"10.1016\/j.xphs.2023.05.014_bib0017","doi-asserted-by":"crossref","first-page":"911","DOI":"10.3390\/ph15080911","article-title":"Immunogenicity of current and new therapies for hemophilia A","volume":"15","author":"Prezotti","year":"2022","journal-title":"Pharmaceuticals"},{"issue":"7","key":"10.1016\/j.xphs.2023.05.014_bib0018","doi-asserted-by":"crossref","first-page":"849","DOI":"10.3324\/haematol.2015.129858","article-title":"The search for the origin of factor VIII synthesis and its impact on therapeutic strategies for hemophilia A","volume":"100","author":"Arruda","year":"2015","journal-title":"Haematologica"},{"issue":"5992","key":"10.1016\/j.xphs.2023.05.014_bib0019","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/312337a0","article-title":"Structure of human factor VIII","volume":"312","author":"Vehar","year":"1984","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.xphs.2023.05.014_bib0020","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0021-9258(19)40122-1","article-title":"Binding of human factor VIII to phospholipid vesicles","volume":"265","author":"Gilbert","year":"1990","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1016\/j.xphs.2023.05.014_bib0021","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/ajh.2830160312","article-title":"Factor VIII: structure and function in blood clotting","volume":"16","author":"Chavin","year":"1984","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.xphs.2023.05.014_bib0022","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1111\/j.1538-7836.2005.01389.x","article-title":"The B domain of coagulation factor VIII interacts with the asialoglycoprotein receptor","volume":"3","author":"Bovenschen","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"11","key":"10.1016\/j.xphs.2023.05.014_bib0023","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1182\/blood.V106.11.687.687","article-title":"The secretion efficiency of factor viII can be regulated by the size and oligosaccharide content of the B domain","volume":"106","author":"Pipe","year":"2005","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.xphs.2023.05.014_bib0024","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/01.mbc.0000233368.95733.3c","article-title":"Role of the B domain in proteolytic inactivation of activated coagulation factor VIII by activated protein C and activated factor X","volume":"17","author":"Khrenov","year":"2006","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"35","key":"10.1016\/j.xphs.2023.05.014_bib0025","doi-asserted-by":"crossref","first-page":"10760","DOI":"10.1021\/bi970052+","article-title":"The physical exchange of factor VIII (FVIII) between von Willebrand factor and activated platelets and the effect of the FVIII B-domain on platelet binding","volume":"36","author":"Li","year":"1997","journal-title":"Biochemistry"},{"issue":"16","key":"10.1016\/j.xphs.2023.05.014_bib0026","doi-asserted-by":"crossref","first-page":"5939","DOI":"10.1073\/pnas.83.16.5939","article-title":"A large region (approximately equal to 95kDa) of human factor VIII is dispensable for in vitro procoagulant activity","volume":"83","author":"Toole","year":"1986","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6760","key":"10.1016\/j.xphs.2023.05.014_bib0027","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/46601","article-title":"Structure of the C2 domain of human factor VIII at 1.5 A resolution","volume":"402","author":"Pratt","year":"1999","journal-title":"Nature"},{"issue":"43","key":"10.1016\/j.xphs.2023.05.014_bib0028","doi-asserted-by":"crossref","first-page":"27918","DOI":"10.1074\/jbc.273.43.27918","article-title":"Activation of factor VIII by thrombin increases its affinity for binding to synthetic phospholipid membranes and activated platelets","volume":"273","author":"Saenko","year":"1998","journal-title":"J Biol Chem"},{"issue":"4","key":"10.1016\/j.xphs.2023.05.014_bib0029","doi-asserted-by":"crossref","first-page":"686","DOI":"10.3324\/haematol.2016.153163","article-title":"Factor VIII\/V C-domain swaps reveal discrete C-domain roles in factor VIII function and intracellular trafficking","volume":"102","author":"Ebberink","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.xphs.2023.05.014_bib0030","series-title":"Recent Advances in Thrombosis and Hemostasis 2008","first-page":"45","article-title":"Synthesis and secretion of coagulation factor VIII","author":"Callaghan","year":"2008"},{"issue":"3","key":"10.1016\/j.xphs.2023.05.014_bib0031","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/0268-960X(89)90015-5","article-title":"Factor VIII structure and function","volume":"3","author":"Foster","year":"1989","journal-title":"Blood Rev"},{"issue":"4","key":"10.1016\/j.xphs.2023.05.014_bib0032","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0887-7963(92)70174-6","article-title":"Expression and structure-function properties of recombinant factor VIII","volume":"6","author":"Kaufman","year":"1992","journal-title":"Transfus Med Rev"},{"issue":"16","key":"10.1016\/j.xphs.2023.05.014_bib0033","doi-asserted-by":"crossref","first-page":"5939","DOI":"10.1073\/pnas.83.16.5939","article-title":"A large region (approximately equal to 95kDa) of human factor VIII is dispensable for in vitro procoagulant activity","volume":"83","author":"Toole","year":"1986","journal-title":"Proc Natl Acad Sci"},{"issue":"12","key":"10.1016\/j.xphs.2023.05.014_bib0034","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1111\/j.1538-7836.2009.03622.x","article-title":"The molecular basis of factor V and VIII procofactor activation","volume":"7","author":"Camire","year":"2009","journal-title":"J Thromb Haemost"},{"issue":"9215","key":"10.1016\/j.xphs.2023.05.014_bib0035","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/S0140-6736(00)02225-X","article-title":"Blood coagulation","volume":"355","author":"Dahlb\u00e4ck","year":"2000","journal-title":"Lancet North Am Ed"},{"issue":"1","key":"10.1016\/j.xphs.2023.05.014_bib0036","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood-2008-06-160432","article-title":"How we treat a hemophilia A patient with a factor VIII inhibitor","volume":"113","author":"Kempton","year":"2009","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.xphs.2023.05.014_bib0037","doi-asserted-by":"crossref","first-page":"4046","DOI":"10.1182\/blood-2012-09-457036","article-title":"Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study","volume":"121","author":"Gouw","year":"2013","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.xphs.2023.05.014_bib0038","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1111\/j.1538-7836.2010.03823.x","article-title":"Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review","volume":"8","author":"Iorio","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"3","key":"10.1016\/j.xphs.2023.05.014_bib0039","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1182\/blood.2019000658","article-title":"Timing of inhibitor development in more than 1000 previously untreated patients with severe hemophilia A","volume":"134","author":"van den Berg","year":"2019","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.xphs.2023.05.014_bib0040","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1111\/j.1538-7836.2004.00802.x","article-title":"Pathogenic antibodies to coagulation factors. Part one: factor VIII and factor IX","volume":"2","author":"Lollar","year":"2004","journal-title":"J Thromb Haemost"},{"issue":"8","key":"10.1016\/j.xphs.2023.05.014_bib0041","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1182\/blood.V82.8.2452.2452","article-title":"Anti-factor VIII antibodies of hemophiliac patients are frequently directed towards nonfunctional determinants and do not exhibit isotypic restriction","volume":"82","author":"Gilles","year":"1993","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.xphs.2023.05.014_bib0042","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1182\/blood.V69.5.1475.1475","article-title":"FVIII inhibitor IgG subclass and FVIII polypeptide specificity determined by immunoblotting","volume":"69","author":"Fulcher","year":"1987","journal-title":"Blood"},{"key":"10.1016\/j.xphs.2023.05.014_bib0043","first-page":"73","article-title":"Immunochemical characterization of factor VIII inhibitors","volume":"150","author":"Hoyer","year":"1984","journal-title":"Prog Clin Biol Res"},{"issue":"5","key":"10.1016\/j.xphs.2023.05.014_bib0044","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1182\/blood.V74.5.1618.1618","article-title":"Localization of epitopes for human factor VIII inhibitor antibodies by immunoblotting and antibody neutralization","volume":"74","author":"Scandella","year":"1989","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.xphs.2023.05.014_bib0045","doi-asserted-by":"crossref","first-page":"7728","DOI":"10.1073\/pnas.82.22.7728","article-title":"Localization of human factor FVIII inhibitor epitopes to two polypeptide fragments","volume":"82","author":"Fulcher","year":"1985","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"10.1016\/j.xphs.2023.05.014_bib0046","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1172\/JCI117259","article-title":"Inhibition of human factor VIIIa by anti-A2 subunit antibodies","volume":"93","author":"Lollar","year":"1994","journal-title":"J Clin Invest"},{"issue":"5","key":"10.1016\/j.xphs.2023.05.014_bib0047","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1182\/blood.V86.5.1811.bloodjournal8651811","article-title":"Some factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248 through 2312, which overlap a phospholipid-binding site","volume":"86","author":"Scandella","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.xphs.2023.05.014_bib0048","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.cellimm.2015.12.008","article-title":"Recombinant factor VIII Fc (rFVIIIFc) fusion protein reduces immunogenicity and induces tolerance in hemophilia A mice","volume":"301","author":"Krishnamoorthy","year":"2016","journal-title":"Cell Immunol"},{"key":"10.1016\/j.xphs.2023.05.014_bib0049","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3389\/fimmu.2020.00138","article-title":"Recombinant factor VIII Fc inhibits B cell activation via engagement of the FcgammaRIIB receptor","volume":"11","author":"Georgescu","year":"2020","journal-title":"Front Immunol"},{"issue":"8","key":"10.1016\/j.xphs.2023.05.014_bib0050","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.1182\/blood-2008-02-138073","article-title":"Activation of natural regulatory T cells by IgG Fc-derived peptide \"Tregitopes\"","volume":"112","author":"De Groot","year":"2008","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.xphs.2023.05.014_bib0051","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1111\/jth.12911","article-title":"Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A","volume":"13","author":"Young","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"3","key":"10.1016\/j.xphs.2023.05.014_bib0052","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1182\/blood-2013-10-529974","article-title":"Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A","volume":"123","author":"Mahlangu","year":"2014","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.xphs.2023.05.014_bib0053","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/hae.13953","article-title":"Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: final results from the ASPIRE extension study","volume":"26","author":"Nolan","year":"2020","journal-title":"Haemophilia"},{"issue":"26","key":"10.1016\/j.xphs.2023.05.014_bib0054","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1182\/blood.2021013563","article-title":"First study of extended half-life rFVIIIFc in previously untreated patients with hemophilia A: PUPs A-LONG final results","volume":"139","author":"Konigs","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.xphs.2023.05.014_bib0055","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.thromres.2020.07.004","article-title":"Observational study of recombinant factor VIII-Fc, rFVIIIFc, in hemophilia A","volume":"195","author":"Ebbert","year":"2020","journal-title":"Thromb Res"},{"key":"10.1016\/j.xphs.2023.05.014_bib0056","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.cellimm.2015.12.006","article-title":"Immunogenicity of long-lasting recombinant factor VIII products","volume":"301","author":"Ing","year":"2016","journal-title":"Cell Immunol"},{"key":"10.1016\/j.xphs.2023.05.014_bib0057","first-page":"119","article-title":"Fc Receptors in antimicrobial protection","volume":"423","author":"Wieland","year":"2019","journal-title":"Curr Top Microbiol Immunol"},{"issue":"45","key":"10.1016\/j.xphs.2023.05.014_bib0058","doi-asserted-by":"crossref","first-page":"6601","DOI":"10.1016\/j.vaccine.2021.09.077","article-title":"Development of an IgG-Fc fusion COVID-19 subunit vaccine, AKS-452","volume":"39","author":"Alleva","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.xphs.2023.05.014_bib0059","doi-asserted-by":"crossref","first-page":"932","DOI":"10.3389\/fimmu.2018.00932","article-title":"Immunization with Fc-based recombinant Epstein-Barr virus gp350 elicits potent neutralizing humoral immune response in a BALB\/c mice model","volume":"9","author":"Zhao","year":"2018","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.xphs.2023.05.014_bib0060","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1053\/j.seminhematol.2003.11.016","article-title":"Environmental and genetic factors influencing inhibitor development","volume":"41","author":"Oldenburg","year":"2004","journal-title":"Semin Hematol"},{"issue":"12","key":"10.1016\/j.xphs.2023.05.014_bib0061","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1182\/blood-2011-09-379453","article-title":"F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis","volume":"119","author":"Gouw","year":"2012","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.xphs.2023.05.014_bib0062","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1365-2516.2006.01361.x","article-title":"Genetic risk factors for inhibitors to factors VIII and IX","volume":"12","author":"Oldenburg","year":"2006","journal-title":"Haemophilia"},{"issue":"10","key":"10.1016\/j.xphs.2023.05.014_bib0063","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1038\/nm.3270","article-title":"Endogenous factor VIII synthesis from the intron 22-inverted F8 locus may modulate the immunogenicity of replacement therapy for hemophilia A","volume":"19","author":"Pandey","year":"2013","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.xphs.2023.05.014_bib0064","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1182\/blood-2013-12-530113","article-title":"The intron-22-inverted F8 locus permits factor VIII synthesis: explanation for low inhibitor risk and a role for pharmacogenomics","volume":"125","author":"Sauna","year":"2015","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.xphs.2023.05.014_bib0065","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/j.1365-2516.2011.02700.x","article-title":"F8 and F9 mutations in US haemophilia patients: correlation with history of inhibitor and race\/ethnicity","volume":"18","author":"Miller","year":"2012","journal-title":"Haemophilia"},{"issue":"3","key":"10.1016\/j.xphs.2023.05.014_bib0066","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1046\/j.1365-2516.2001.00510.x","article-title":"The Malmo International Brother Study (MIBS): further support for genetic predisposition to inhibitor development in hemophilia patients","volume":"7","author":"Astermark","year":"2001","journal-title":"Haemophilia"},{"issue":"1","key":"10.1016\/j.xphs.2023.05.014_bib0067","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1046\/j.1365-2516.1998.0146c.x","article-title":"Inhibitors occur more frequently in African-American and Latino haemophiliacs","volume":"4","author":"Aledort","year":"1998","journal-title":"Haemophilia"},{"issue":"3","key":"10.1016\/j.xphs.2023.05.014_bib0068","doi-asserted-by":"crossref","first-page":"e260","DOI":"10.1111\/j.1365-2516.2011.02739.x","article-title":"Increased prevalence of inhibitors in Hispanic patients with severe haemophilia A enrolled in the Universal Data Collection database","volume":"18","author":"Carpenter","year":"2012","journal-title":"Haemophilia"},{"issue":"16","key":"10.1016\/j.xphs.2023.05.014_bib0069","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1056\/NEJMoa075760","article-title":"Inhibitors of factor VIII in black patients with hemophilia","volume":"360","author":"Viel","year":"2009","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.xphs.2023.05.014_bib0070","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1182\/blood-2014-09-599365","article-title":"Factor VIII gene variants and inhibitor risk in African American hemophilia A patients","volume":"126","author":"Gunasekera","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.xphs.2023.05.014_bib0071","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/hae.12004","article-title":"F8 haplotype and inhibitor risk: results from the Hemophilia Inhibitor Genetics Study (HIGS) combined cohort","volume":"19","author":"Schwarz","year":"2013","journal-title":"Haemophilia"},{"issue":"5","key":"10.1016\/j.xphs.2023.05.014_bib0072","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/hae.12436","article-title":"Genetic factors influencing inhibitor development in a cohort of South African haemophilia A patients","volume":"20","author":"Lochan","year":"2014","journal-title":"Haemophilia"},{"issue":"3","key":"10.1016\/j.xphs.2023.05.014_bib0073","first-page":"309","article-title":"Inhibitors of factor VIII in hemophilia","volume":"361","author":"Eckhardt","year":"2009","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.xphs.2023.05.014_bib0074","first-page":"309","article-title":"Inhibitors of factor VIII in hemophilia","volume":"361","author":"Peyvandi","year":"2009","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.xphs.2023.05.014_bib0075","first-page":"309","article-title":"Inhibitors of factor VIII in hemophilia","volume":"361","author":"Santos","year":"2009","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.xphs.2023.05.014_bib0076","first-page":"500","article-title":"The role of genetics in inhibitor formation","volume":"82","author":"Gill","year":"1999","journal-title":"Thromb Haemost"},{"issue":"5","key":"10.1016\/j.xphs.2023.05.014_bib0077","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1136\/jcp.2009.072371","article-title":"The HLA system: immunobiology, HLA typing, antibody screening and crossmatching techniques","volume":"63","author":"Howell","year":"2010","journal-title":"J Clin Pathol"},{"issue":"1","key":"10.1016\/j.xphs.2023.05.014_bib0078","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/BF02867546","article-title":"The HLA genes and their diverse polymorphism","volume":"15","author":"Mehra","year":"2000","journal-title":"Indian J Clin Biochem"},{"issue":"1","key":"10.1016\/j.xphs.2023.05.014_bib0079","first-page":"105","article-title":"Polymorphism and evolution of HLA class I and II genes and molecules","volume":"1","author":"Little","year":"1999","journal-title":"Rev Immunogenet"},{"key":"10.1016\/j.xphs.2023.05.014_bib0080","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1146\/annurev-genom-091212-153455","article-title":"Major histocompatibility complex genomics and human disease","volume":"14","author":"Trowsdale","year":"2013","journal-title":"Annu Rev Genomics Hum Genet"},{"issue":"2","key":"10.1016\/j.xphs.2023.05.014_bib0081","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/j.1365-2141.1990.tb07878.x","article-title":"Histocompatibility antigen patterns in haemophilic patients with factor VIII antibodies","volume":"76","author":"Aly","year":"1990","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.xphs.2023.05.014_bib0082","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1055\/s-0038-1653453","article-title":"HLA antigens and factor VIII antibody in classic hemophilia. European study group of factor VIII antibody","volume":"46","author":"Frommel","year":"1981","journal-title":"Thromb Haemost"},{"issue":"4","key":"10.1016\/j.xphs.2023.05.014_bib0083","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1055\/s-0038-1647359","article-title":"Relationship of major histocompatibility complex class II genes to inhibitor antibody formation in hemophilia A","volume":"64","author":"Lippert","year":"1990","journal-title":"Thromb Haemost"},{"issue":"2","key":"10.1016\/j.xphs.2023.05.014_bib0084","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1055\/s-0038-1661081","article-title":"HLA-DR and factor VIII antibodies in hemophilia A","volume":"51","author":"Mayr","year":"1984","journal-title":"Thromb Haemost"},{"issue":"2","key":"10.1016\/j.xphs.2023.05.014_bib0085","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1055\/s-0038-1655944","article-title":"HLA class II profile: a weak determinant of factor VIII inhibitor development in severe haemophilia A. UKHCDO inhibitor working party","volume":"77","author":"Hay","year":"1997","journal-title":"Thromb Haemost"},{"issue":"102","key":"10.1016\/j.xphs.2023.05.014_bib0086","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1365-2516.2008.01976.x","article-title":"HLA genotype in patients with acquired haemophilia A","volume":"16","author":"Pavlova","year":"2010","journal-title":"Haemophilia"},{"issue":"2","key":"10.1016\/j.xphs.2023.05.014_bib0087","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1055\/s-0038-1655945","article-title":"HLA genotype of patients with severe haemophilia A due to intron 22 inversion with and without inhibitors of factor VIII","volume":"77","author":"Oldenburg","year":"1997","journal-title":"Thromb Haemost"},{"issue":"1","key":"10.1016\/j.xphs.2023.05.014_bib0088","first-page":"52","article-title":"Immune-related gene polymorphisms as risk factors for the development of Factor VIII inhibitors in hemophilia A patients: a sibling-pair association analysis (HUM1P.257)","volume":"194","author":"Ferrante","year":"2015","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.xphs.2023.05.014_bib0089","doi-asserted-by":"crossref","first-page":"34","DOI":"10.5505\/tjh.2012.29795","article-title":"The association between HLA class II alleles and the occurrence of factor VIII inhibitor in Thai patients with hemophilia A","volume":"29","author":"Nathalang","year":"2012","journal-title":"Turk J Haematol"},{"issue":"3","key":"10.1016\/j.xphs.2023.05.014_bib0090","doi-asserted-by":"crossref","first-page":"e236","DOI":"10.1111\/j.1365-2516.2011.02604.x","article-title":"Influence of class I and II HLA alleles on inhibitor development in severe haemophilia A patients from the south of Brazil","volume":"18","author":"De Barros","year":"2012","journal-title":"Haemophilia"},{"issue":"1","key":"10.1016\/j.xphs.2023.05.014_bib0091","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1034\/j.1399-0039.1999.540111.x","article-title":"Histocompatibility antigens and alleles in Japanese haemophilia A patients with or without factor VIII antibodies","volume":"54","author":"Ohta","year":"1999","journal-title":"Tissue Antigens"},{"issue":"5","key":"10.1016\/j.xphs.2023.05.014_bib0092","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.transci.2019.08.019","article-title":"HLA-DRB1*01:01, but not HLA-DRB1:1503 or HLA-DRB1\u00d711, is associated with decreased inhibitor risk in Iranian hemophilia A patients","volume":"58","author":"Hosseini","year":"2019","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.xphs.2023.05.014_bib0093","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.663396","article-title":"HLA variants and inhibitor development in hemophilia A: a retrospective case-controlled study using the ATHNdataset","volume":"8","author":"McGill","year":"2021","journal-title":"Front Med"},{"issue":"3","key":"10.1016\/j.xphs.2023.05.014_bib0094","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.clim.2013.09.006","article-title":"T-cell dependent immunogenicity of protein therapeutics: preclinical assessment and mitigation","volume":"149","author":"Jawa","year":"2013","journal-title":"Clin Immunol"},{"issue":"9","key":"10.1016\/j.xphs.2023.05.014_bib0095","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1182\/bloodadvances.2018030452","article-title":"Peptides identified on monocyte-derived dendritic cells: a marker for clinical immunogenicity to FVIII products","volume":"3","author":"Jankowski","year":"2019","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.xphs.2023.05.014_bib0096","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/sj.gene.6364301","article-title":"Cytokine gene polymorphism in human disease: on-line databases, Supplement 3","volume":"7","author":"Hollegaard","year":"2006","journal-title":"Genes Immun"},{"issue":"4","key":"10.1016\/j.xphs.2023.05.014_bib0097","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1089\/jir.2011.0103","article-title":"Cytokine gene polymorphisms and human autoimmune disease in the era of genome-wide association studies","volume":"32","author":"Vandenbroeck","year":"2012","journal-title":"J Interferon Cytokine Res"},{"issue":"2","key":"10.1016\/j.xphs.2023.05.014_bib0098","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1385\/IR:30:2:181","article-title":"Cytokine polymorphism and its possible impact on cancer","volume":"30","author":"Jin","year":"2004","journal-title":"Immunol Res"},{"issue":"8","key":"10.1016\/j.xphs.2023.05.014_bib0099","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1182\/blood-2005-09-3918","article-title":"Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A","volume":"107","author":"Astermark","year":"2006","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.xphs.2023.05.014_bib0100","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1111\/j.1538-7836.2009.03636.x","article-title":"Impact of polymorphisms of the major histocompatibility complex class II, interleukin-10, tumor necrosis factor-alpha and cytotoxic T-lymphocyte antigen-4 genes on inhibitor development in severe hemophilia A","volume":"7","author":"Pavlova","year":"2009","journal-title":"J Thromb Haemost"},{"issue":"2","key":"10.1016\/j.xphs.2023.05.014_bib0101","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1744-313X.2009.00893.x","article-title":"Analysis of cytokine genes polymorphism as markers for inhibitor development in haemophilia A","volume":"37","author":"Chaves","year":"2010","journal-title":"Int J Immunogenet"},{"issue":"4","key":"10.1016\/j.xphs.2023.05.014_bib0102","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/j.1365-2516.2010.02473.x","article-title":"A case-control study reveals immunoregulatory gene haplotypes that influence inhibitor risk in severe haemophilia A","volume":"17","author":"Lozier","year":"2011","journal-title":"Haemophilia"},{"issue":"1","key":"10.1016\/j.xphs.2023.05.014_bib0103","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1160\/TH11-06-0425","article-title":"Impact of polymorphisms in genes involved in autoimmune disease on inhibitor development in Chinese patients with haemophilia A","volume":"107","author":"Lu","year":"2012","journal-title":"Thromb Haemost"},{"issue":"5","key":"10.1016\/j.xphs.2023.05.014_bib0104","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1111\/j.1365-2516.2012.02845.x","article-title":"Immune regulatory gene polymorphisms as predisposing risk factors for the development of factor VIII inhibitors in Indian severe haemophilia A patients","volume":"18","author":"Pinto","year":"2012","journal-title":"Haemophilia"},{"issue":"5","key":"10.1016\/j.xphs.2023.05.014_bib0105","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1111\/hae.12168","article-title":"Impact of HLA alleles and cytokine polymorphisms on inhibitors development in children with severe haemophilia A","volume":"19","author":"Pergantou","year":"2013","journal-title":"Haemophilia"},{"key":"10.1016\/j.xphs.2023.05.014_bib0106","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1146\/annurev-immunol-031210-101312","article-title":"Regulation and functions of the IL-10 family of cytokines in inflammation and disease","volume":"29","author":"Ouyang","year":"2011","journal-title":"Annu Rev Immunol"},{"issue":"1","key":"10.1016\/j.xphs.2023.05.014_bib0107","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1615\/CritRevImmunol.v32.i1.30","article-title":"Role of interleukin 10 transcriptional regulation in inflammation and autoimmune disease","volume":"32","author":"Iyer","year":"2012","journal-title":"Crit Rev Immunol"},{"issue":"1","key":"10.1016\/j.xphs.2023.05.014_bib0108","doi-asserted-by":"crossref","first-page":"17","DOI":"10.4274\/Tjh.2012.0197","article-title":"A polymorphism in the IL-5 gene is associated with inhibitor development in severe hemophilia A patients","volume":"31","author":"Fidanci","year":"2014","journal-title":"Turk J Haematol"},{"issue":"13","key":"10.1016\/j.xphs.2023.05.014_bib0109","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1182\/blood-2014-08-535328","article-title":"FVIII inhibitors: pathogenesis and avoidance","volume":"125","author":"Astermark","year":"2015","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.xphs.2023.05.014_bib0110","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/blood-2006-05-024711","article-title":"Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A","volume":"108","author":"Astermark","year":"2006","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.xphs.2023.05.014_bib0111","first-page":"168","article-title":"Relationship between factor VIII inhibitor development and polymorphisms of TNFalpha and CTLA-4 gene in Chinese Han patients with hemophilia A","volume":"32","author":"Zhang","year":"2011","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"10","key":"10.1016\/j.xphs.2023.05.014_bib0112","doi-asserted-by":"crossref","first-page":"4981","DOI":"10.1177\/0300060519860329","article-title":"Polymorphisms in the cytotoxic T lymphocyte-associated protein-4 immune regulatory gene and their impact on inhibitor development in patients with hemophilia A","volume":"47","author":"Abdulqader","year":"2019","journal-title":"J Int Med Res"},{"issue":"8","key":"10.1016\/j.xphs.2023.05.014_bib0113","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1182\/blood-2012-06-434803","article-title":"The polygenic nature of inhibitors in hemophilia A: results from the Hemophilia Inhibitor Genetics Study (HIGS) combined cohort","volume":"121","author":"Astermark","year":"2013","journal-title":"Blood"},{"issue":"162","key":"10.1016\/j.xphs.2023.05.014_bib0114","first-page":"59","article-title":"Investigating the IGSF2 and TNF\u03b1 genes polymorphism and the risk of inhibitor development in patients with hemophilia A","volume":"28","author":"Seyed Mikaeili","year":"2018","journal-title":"J Mazandaran Univ Med Sci"},{"issue":"3","key":"10.1016\/j.xphs.2023.05.014_bib0115","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1046\/j.1365-2141.2001.02828.x","article-title":"Incidence of factor VIII inhibitors in severe haemophilia: the importance of patient age","volume":"113","author":"Lorenzo","year":"2001","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.xphs.2023.05.014_bib0116","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1055\/s-0037-1613376","article-title":"Age at first treatment and immune tolerance to factor VIII in severe hemophilia","volume":"89","author":"van der Bom","year":"2003","journal-title":"Thromb Haemost"},{"issue":"1","key":"10.1016\/j.xphs.2023.05.014_bib0117","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1182\/blood-2005-04-1371","article-title":"Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A","volume":"107","author":"Goudemand","year":"2006","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.xphs.2023.05.014_bib0118","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1177\/2040620712464509","article-title":"Factor VIII inhibitors in hemophilia A: rationale and latest evidence","volume":"4","author":"Witmer","year":"2013","journal-title":"Ther Adv Hematol"},{"issue":"2","key":"10.1016\/j.xphs.2023.05.014_bib0119","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1365-2516.2006.01418.x","article-title":"Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A","volume":"13","author":"Chalmers","year":"2007","journal-title":"Haemophilia"},{"issue":"11","key":"10.1016\/j.xphs.2023.05.014_bib0120","doi-asserted-by":"crossref","first-page":"4648","DOI":"10.1182\/blood-2006-11-056291","article-title":"Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study","volume":"109","author":"Gouw","year":"2007","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.xphs.2023.05.014_bib0121","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/j.1365-2141.2005.05605.x","article-title":"Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study","volume":"130","author":"Santagostino","year":"2005","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.xphs.2023.05.014_bib0122","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/j.1365-2516.2010.02422.x","article-title":"Treatment related factors and inhibitor development in children with severe haemophilia A","volume":"17","author":"Maclean","year":"2011","journal-title":"Haemophilia"},{"issue":"6","key":"10.1016\/j.xphs.2023.05.014_bib0123","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1365-2516.2006.01362.x","article-title":"The epidemiology of factor VIII inhibitors","volume":"12","author":"Hay","year":"2006","journal-title":"Haemophilia"},{"issue":"6","key":"10.1016\/j.xphs.2023.05.014_bib0124","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1046\/j.1538-7836.2003.00230.x","article-title":"Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia A","volume":"1","author":"Sharathkumar","year":"2003","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.xphs.2023.05.014_bib0125","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1196\/annals.1361.094","article-title":"Inhibitor development in patients with hemophilia A after continuous infusion of FVIII concentrates","volume":"1051","author":"von Auer","year":"2005","journal-title":"Ann N Y Acad Sci"},{"issue":"5","key":"10.1016\/j.xphs.2023.05.014_bib0126","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/hae.13042","article-title":"Schutgens RE. First preclinical support for the 'danger theory' in inhibitor development","volume":"22","author":"van Vulpen","year":"2016","journal-title":"Haemophilia"},{"issue":"5","key":"10.1016\/j.xphs.2023.05.014_bib0127","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1080\/17474086.2019.1604213","article-title":"An update on the 'danger theory' in inhibitor development in hemophilia A","volume":"12","author":"Schep","year":"2019","journal-title":"Expert Rev Hematol"},{"issue":"6","key":"10.1016\/j.xphs.2023.05.014_bib0128","doi-asserted-by":"crossref","first-page":"vi3","DOI":"10.1093\/ndt\/gfh1092","article-title":"Factors influencing the immunogenicity of therapeutic proteins","volume":"20","author":"Schellekens","year":"2005","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"10.1016\/j.xphs.2023.05.014_bib0129","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/j.xphs.2018.12.014","article-title":"Immunogenicity of protein pharmaceuticals","volume":"108","author":"Dingman","year":"2019","journal-title":"J Pharm Sci"},{"issue":"14","key":"10.1016\/j.xphs.2023.05.014_bib0130","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jama.2011.406","article-title":"Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up","volume":"305","author":"Bartelds","year":"2011","journal-title":"JAMA"},{"issue":"15","key":"10.1016\/j.xphs.2023.05.014_bib0131","doi-asserted-by":"crossref","first-page":"11601","DOI":"10.1016\/S0021-9258(19)78167-8","article-title":"A role for the C2 domain of factor VIII in binding to von Willebrand factor","volume":"269","author":"Saenko","year":"1994","journal-title":"J Biol Chem"},{"issue":"29","key":"10.1016\/j.xphs.2023.05.014_bib0132","doi-asserted-by":"crossref","first-page":"18007","DOI":"10.1074\/jbc.272.29.18007","article-title":"The acidic region of the factor VIII light chain and the C2 domain together form the high affinity binding site for von willebrand factor","volume":"272","author":"Saenko","year":"1997","journal-title":"J Biol Chem"},{"issue":"6","key":"10.1016\/j.xphs.2023.05.014_bib0133","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1002\/jps.20340","article-title":"Lipid binding region (2303-2332) is involved in aggregation of recombinant human FVIII (rFVIII)","volume":"94","author":"Ramani","year":"2005","journal-title":"J Pharm Sci"},{"issue":"3","key":"10.1016\/j.xphs.2023.05.014_bib0134","first-page":"522","article-title":"Immunodominant T-cell epitopes in the factor VIII C2 domain are located within an inhibitory antibody binding site","volume":"92","author":"Pratt","year":"2004","journal-title":"Thromb Haemost"},{"issue":"8","key":"10.1016\/j.xphs.2023.05.014_bib0135","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1046\/j.1538-7836.2003.00251.x","article-title":"Human CD4+ T-cell epitope repertoire on the C2 domain of coagulation factor VIII","volume":"1","author":"Reding","year":"2003","journal-title":"J Thromb Haemost"},{"issue":"21","key":"10.1016\/j.xphs.2023.05.014_bib0136","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1056\/NEJMoa1516437","article-title":"A randomized trial of factor VIII and neutralizing antibodies in hemophilia A","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.xphs.2023.05.014_bib0137","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/hae.12465","article-title":"Novel investigations on the protective role of the FVIII\/VWF complex in inhibitor development","volume":"20","author":"Mannucci","year":"2014","journal-title":"Haemophilia"},{"issue":"2","key":"10.1016\/j.xphs.2023.05.014_bib0138","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1182\/blood-2006-05-022756","article-title":"VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors","volume":"109","author":"Dasgupta","year":"2007","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.xphs.2023.05.014_bib0139","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/j.1365-2516.2011.02679.x","article-title":"Immunoprotective effect of von Willebrand factor towards therapeutic factor VIII in experimental haemophilia A","volume":"18","author":"Delignat","year":"2012","journal-title":"Haemophilia"},{"issue":"3","key":"10.1016\/j.xphs.2023.05.014_bib0140","doi-asserted-by":"crossref","first-page":"309","DOI":"10.3324\/haematol.2015.137067","article-title":"von Willebrand factor binds to the surface of dendritic cells and modulates peptide presentation of factor VIII","volume":"101","author":"Sorvillo","year":"2016","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.xphs.2023.05.014_bib0141","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/hae.14589","article-title":"Plasma-derived FVIII\/VWF complex shows higher protection against inhibitors than isolated FVIII after infusion in haemophilic patients: a translational study","volume":"28","author":"Bravo","year":"2022","journal-title":"Haemophilia"},{"issue":"11","key":"10.1016\/j.xphs.2023.05.014_bib0142","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMoa2002699","article-title":"BIVV001 fusion protein as factor VIII replacement therapy for hemophilia A","volume":"383","author":"Konkle","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.xphs.2023.05.014_bib0143","series-title":"ALTUVIIIO [Package Insert]","year":"2023"},{"issue":"4","key":"10.1016\/j.xphs.2023.05.014_bib0144","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2209226","article-title":"Efanesoctocog alfa prophylaxis for patients with severe hemophilia A","volume":"388","author":"von Drygalski","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.xphs.2023.05.014_bib0145","unstructured":"Sanofi. Press release: completed XTEND-kids phase 3 study strengthens potential of ALTUVIIIO\u2122 to redefine expectations for treatment of children <12 years of age with hemophilia A 2023. Available from: https:\/\/www.sanofi.com\/en\/media-room\/press-releases\/2023\/2023-03-02-07-00-00-2618928."},{"issue":"2","key":"10.1016\/j.xphs.2023.05.014_bib0146","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.xphs.2015.11.002","article-title":"Immunogenicity of therapeutic protein aggregates","volume":"105","author":"Moussa","year":"2016","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2023.05.014_bib0147","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/401956","article-title":"The role of aggregates of therapeutic protein products in immunogenicity: an evaluation by mathematical modeling","volume":"2015","author":"Yin","year":"2015","journal-title":"J Immunol Res"},{"issue":"6","key":"10.1016\/j.xphs.2023.05.014_bib0148","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1007\/s11095-013-0992-9","article-title":"Effect of treatment regimen on the immunogenicity of human interferon Beta in immune tolerant mice","volume":"30","author":"Kijanka","year":"2013","journal-title":"Pharm Res"},{"key":"10.1016\/j.xphs.2023.05.014_bib0149","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.122490","article-title":"In vitro and in vivo immunogenicity assessment of protein aggregate characteristics","volume":"631","author":"Thorlaksen","year":"2023","journal-title":"Int J Pharm"},{"issue":"7","key":"10.1016\/j.xphs.2023.05.014_bib0150","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1093\/ndt\/gfg164","article-title":"Immunogenicity of therapeutic proteins","volume":"18","author":"Schellekens","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"3","key":"10.1016\/j.xphs.2023.05.014_bib0151","doi-asserted-by":"crossref","first-page":"E501","DOI":"10.1208\/aapsj080359","article-title":"Effects of protein aggregates: an immunologic perspective","volume":"8","author":"Rosenberg","year":"2006","journal-title":"AAPS J"},{"issue":"6","key":"10.1016\/j.xphs.2023.05.014_bib0152","first-page":"423","article-title":"Recognition and identification of UV-absorbing leachables in EPREX\u00ae pre-filled syringes: an unexpected occurrence at a formulation\u2014component interface","volume":"61","author":"Pang","year":"2007","journal-title":"PDA J Pharm Sci Technol"},{"issue":"6","key":"10.1016\/j.xphs.2023.05.014_bib0153","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1111\/j.1523-1755.2005.00340.x","article-title":"The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes","volume":"67","author":"Boven","year":"2005","journal-title":"Kidney Int"},{"issue":"6","key":"10.1016\/j.xphs.2023.05.014_bib0154","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1007\/s11095-011-0621-4","article-title":"Tungsten-induced denaturation and aggregation of epoetin alfa during primary packaging as a cause of immunogenicity","volume":"29","author":"Seidl","year":"2012","journal-title":"Pharm Res"},{"issue":"4","key":"10.1016\/j.xphs.2023.05.014_bib0155","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1007\/s11095-010-0297-1","article-title":"Strategies for the assessment of protein aggregates in pharmaceutical biotech product development","volume":"28","author":"den Engelsman","year":"2011","journal-title":"Pharm Res"},{"issue":"6","key":"10.1016\/j.xphs.2023.05.014_bib0156","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1111\/jth.14125","article-title":"Comparative analysis of marketed factor VIII products: recombinant products are not alike vis-a-vis soluble protein aggregates and subvisible particles","volume":"16","author":"Anzengruber","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"2","key":"10.1016\/j.xphs.2023.05.014_bib0157","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/jth.13917","article-title":"Identification of aggregates in therapeutic formulations of recombinant full-length factor VIII products by sedimentation velocity analytical ultracentrifugation","volume":"16","author":"Healey","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"9","key":"10.1016\/j.xphs.2023.05.014_bib0158","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1002\/jps.20432","article-title":"Aggregation kinetics of recombinant human FVIII (rFVIII)","volume":"94","author":"Ramani","year":"2005","journal-title":"J Pharm Sci"},{"issue":"6","key":"10.1016\/j.xphs.2023.05.014_bib0159","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1002\/jps.23091","article-title":"Native-like aggregates of factor VIII are immunogenic in von Willebrand factor deficient and hemophilia a mice","volume":"101","author":"Pisal","year":"2012","journal-title":"J Pharm Sci"},{"issue":"8","key":"10.1016\/j.xphs.2023.05.014_bib0160","doi-asserted-by":"crossref","first-page":"6374","DOI":"10.1074\/jbc.M104732200","article-title":"Four hydrophobic amino acids of the factor VIII C2 domain are constituents of both the membrane-binding and von Willebrand factor-binding motifs","volume":"277","author":"Gilbert","year":"2002","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.xphs.2023.05.014_bib0161","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3324\/haematol.2017.174706","article-title":"Analyses of the FranceCoag cohort support differences in immunogenicity among one plasma-derived and two recombinant factor VIII brands in boys with severe hemophilia A","volume":"103","author":"Calvez","year":"2018","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.xphs.2023.05.014_bib0162","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1021\/bi001547t","article-title":"Conformational origin of the aggregation of recombinant human factor VIII","volume":"40","author":"Grillo","year":"2001","journal-title":"Biochemistry"},{"issue":"18","key":"10.1016\/j.xphs.2023.05.014_bib0163","doi-asserted-by":"crossref","first-page":"17593","DOI":"10.1074\/jbc.M500163200","article-title":"Lower inhibitor development in hemophilia A mice following administration of recombinant factor VIII-O-phospho-l-serine complex","volume":"280","author":"Purohit","year":"2005","journal-title":"J Biol Chem"},{"issue":"11","key":"10.1016\/j.xphs.2023.05.014_bib0164","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1002\/jps.24173","article-title":"O-phospho-l-serine mediates hyporesponsiveness toward FVIII in hemophilia A-murine model by inducing tolerogenic properties in dendritic cells","volume":"103","author":"Fathallah","year":"2014","journal-title":"J Pharm Sci"},{"issue":"4","key":"10.1016\/j.xphs.2023.05.014_bib0165","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1002\/jps.21102","article-title":"Phosphatidylserine containing liposomes reduce immunogenicity of recombinant human factor VIII (rFVIII) in a murine model of hemophilia A","volume":"97","author":"Ramani","year":"2008","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2023.05.014_bib0166","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s12896-015-0205-1","article-title":"Differences in N-glycosylation of recombinant human coagulation factor VII derived from BHK, CHO, and HEK293 cells","volume":"15","author":"Bohm","year":"2015","journal-title":"BMC Biotechnol"},{"issue":"3","key":"10.1016\/j.xphs.2023.05.014_bib0167","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.jbiotec.2012.06.038","article-title":"Differences in the glycosylation of recombinant proteins expressed in HEK and CHO cells","volume":"161","author":"Croset","year":"2012","journal-title":"J Biotechnol"},{"issue":"3","key":"10.1016\/j.xphs.2023.05.014_bib0168","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1208\/s12248-009-9119-y","article-title":"Role of glycosylation in conformational stability, activity, macromolecular interaction and immunogenicity of recombinant human factor VIII","volume":"11","author":"Kosloski","year":"2009","journal-title":"AAPS J"},{"issue":"15","key":"10.1016\/j.xphs.2023.05.014_bib0169","doi-asserted-by":"crossref","first-page":"8072","DOI":"10.1128\/JVI.00459-07","article-title":"Hepatitis C virus envelope glycoprotein E2 glycans modulate entry, CD81 binding, and neutralization","volume":"81","author":"Falkowska","year":"2007","journal-title":"J Virol"},{"issue":"15","key":"10.1016\/j.xphs.2023.05.014_bib0170","doi-asserted-by":"crossref","first-page":"8101","DOI":"10.1128\/JVI.00127-07","article-title":"The neutralizing activity of anti-hepatitis C virus antibodies is modulated by specific glycans on the E2 envelope protein","volume":"81","author":"Helle","year":"2007","journal-title":"J Virol"},{"issue":"3","key":"10.1016\/j.xphs.2023.05.014_bib0171","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1128\/JVI.78.3.1525-1539.2004","article-title":"Removal of N-linked glycosylation sites in the V1 region of simian immunodeficiency virus gp120 results in redirection of B-cell responses to V3","volume":"78","author":"Cole","year":"2004","journal-title":"J Virol"},{"issue":"6929","key":"10.1016\/j.xphs.2023.05.014_bib0172","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nature01470","article-title":"Antibody neutralization and escape by HIV-1","volume":"422","author":"Wei","year":"2003","journal-title":"Nature"},{"issue":"20","key":"10.1016\/j.xphs.2023.05.014_bib0173","doi-asserted-by":"crossref","first-page":"11432","DOI":"10.1016\/S0021-9258(19)38416-9","article-title":"O-linked sugar chain of human granulocyte colony-stimulating factor protects it against polymerization and denaturation allowing it to retain its biological activity","volume":"265","author":"Oh-eda","year":"1990","journal-title":"J Biol Chem"},{"issue":"4","key":"10.1016\/j.xphs.2023.05.014_bib0174","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1023\/A:1011974512425","article-title":"Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-beta (IFN-beta)","volume":"15","author":"Runkel","year":"1998","journal-title":"Pharm Res"},{"issue":"3","key":"10.1016\/j.xphs.2023.05.014_bib0175","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1002\/jps.23415","article-title":"Characterization and quantitation of aggregates and particles in interferon-beta products: potential links between product quality attributes and immunogenicity","volume":"102","author":"Barnard","year":"2013","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2023.05.014_bib0176","series-title":"Avonex [Package Insert]","year":"2012"},{"key":"10.1016\/j.xphs.2023.05.014_bib0177","series-title":"Betaseron [Package Insert]","year":"2016"},{"key":"10.1016\/j.xphs.2023.05.014_bib0178","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1111\/jth.14204","article-title":"In-depth comparison of N-glycosylation of human plasma-derived factor VIII and different recombinant products: from structure to clinical implications","author":"Canis","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"12","key":"10.1016\/j.xphs.2023.05.014_bib0179","doi-asserted-by":"crossref","first-page":"8012","DOI":"10.1016\/S0021-9258(18)42401-5","article-title":"Comparative study of the sugar chains of factor VIII purified from human plasma and from the culture media of recombinant baby hamster kidney cells","volume":"267","author":"Hironaka","year":"1992","journal-title":"J Biol Chem"},{"issue":"21","key":"10.1016\/j.xphs.2023.05.014_bib0180","doi-asserted-by":"crossref","first-page":"8965","DOI":"10.1073\/pnas.0702120104","article-title":"A role for exposed mannosylations in presentation of human therapeutic self-proteins to CD4+ T lymphocytes","volume":"104","author":"Dasgupta","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"10.1016\/j.xphs.2023.05.014_bib0181","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.jaci.2012.01.048","article-title":"Mannose-sensitive receptors mediate the uptake of factor VIII therapeutics by human dendritic cells","volume":"129","author":"Repesse","year":"2012","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"10.1016\/j.xphs.2023.05.014_bib0182","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1177\/2040620717721458","article-title":"Current and emerging factor VIII replacement products for hemophilia A","volume":"8","author":"Cafuir","year":"2017","journal-title":"Ther Adv Hematol"},{"issue":"2","key":"10.1016\/j.xphs.2023.05.014_bib0183","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/hae.12797","article-title":"Novel, human cell line-derived recombinant factor VIII (Human-cl rhFVIII, Nuwiq((R))) in children with severe haemophilia A: efficacy, safety and pharmacokinetics","volume":"22","author":"Klukowska","year":"2016","journal-title":"Haemophilia"},{"issue":"2","key":"10.1016\/j.xphs.2023.05.014_bib0184","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/hae.12793","article-title":"Novel, human cell line-derived recombinant factor VIII (human-cl rhFVIII; Nuwiq((R))) in adults with severe haemophilia A: efficacy and safety","volume":"22","author":"Lissitchkov","year":"2016","journal-title":"Haemophilia"},{"issue":"3","key":"10.1016\/j.xphs.2023.05.014_bib0185","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/hae.12859","article-title":"Prophylaxis vs. on-demand treatment with Nuwiq((R)) (Human-cl rhFVIII) in adults with severe haemophilia A","volume":"22","author":"Tiede","year":"2016","journal-title":"Haemophilia"},{"issue":"11","key":"10.1016\/j.xphs.2023.05.014_bib0186","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1055\/s-0040-1722623","article-title":"Simoctocog alfa (Nuwiq) in previously untreated patients with severe haemophilia A: final results of the NuProtect study","volume":"121","author":"Liesner","year":"2021","journal-title":"Thromb Haemost"},{"issue":"S1","key":"10.1016\/j.xphs.2023.05.014_bib0187","first-page":"8","article-title":"Final results of PUPs A-LONG study: evaluating safety and efficacy of rFVIIIFc in previously untreated patients with haemophilia A (Abstract)","volume":"4","author":"K\u00f6nigs","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"issue":"4","key":"10.1016\/j.xphs.2023.05.014_bib0188","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1021\/mp200470c","article-title":"Effect of PEGylation on protein hydrodynamics","volume":"9","author":"Gokarn","year":"2012","journal-title":"Mol Pharm"},{"issue":"3","key":"10.1016\/j.xphs.2023.05.014_bib0189","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nrd1033","article-title":"Effect of pegylation on pharmaceuticals","volume":"2","author":"Harris","year":"2003","journal-title":"Nat Rev Drug Discov"},{"issue":"11","key":"10.1016\/j.xphs.2023.05.014_bib0190","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1016\/S0021-9258(17)40291-2","article-title":"Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol","volume":"252","author":"Abuchowski","year":"1977","journal-title":"J Biol Chem"},{"key":"10.1016\/j.xphs.2023.05.014_bib0191","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.cbpa.2016.08.006","article-title":"How PEGylation influences protein conformational stability","volume":"34","author":"Lawrence","year":"2016","journal-title":"Curr Opin Chem Biol"},{"issue":"1\u20132","key":"10.1016\/j.xphs.2023.05.014_bib0192","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.ijpharm.2007.02.011","article-title":"Enhanced solubility and stability of PEGylated liposomal paclitaxel: in vitro and in vivo evaluation","volume":"338","author":"Yang","year":"2007","journal-title":"Int J Pharm"},{"issue":"1","key":"10.1016\/j.xphs.2023.05.014_bib0193","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1529\/biophysj.105.059428","article-title":"Strong repulsive forces between protein and oligo (ethylene glycol) self-assembled monolayers: a molecular simulation study","volume":"89","author":"Zheng","year":"2005","journal-title":"Biophys J"},{"key":"10.1016\/j.xphs.2023.05.014_bib0194","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jconrel.2017.01.029","article-title":"Precise and combinatorial PEGylation generates a low-immunogenic and stable form of human growth hormone","volume":"249","author":"Wu","year":"2017","journal-title":"J Control Release"},{"issue":"5","key":"10.1016\/j.xphs.2023.05.014_bib0195","doi-asserted-by":"crossref","first-page":"866","DOI":"10.3109\/08923973.2012.666979","article-title":"PEGylation is effective in reducing immunogenicity, immunotoxicity, and hepatotoxicity of alpha-momorcharin in vivo","volume":"34","author":"Zheng","year":"2012","journal-title":"Immunopharmacol Immunotoxicol"},{"issue":"36","key":"10.1016\/j.xphs.2023.05.014_bib0196","doi-asserted-by":"crossref","first-page":"6288","DOI":"10.1002\/anie.200902672","article-title":"Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives","volume":"49","author":"Knop","year":"2010","journal-title":"Angew Chem Int Ed Engl"},{"issue":"4","key":"10.1016\/j.xphs.2023.05.014_bib0197","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S0169-409X(02)00026-1","article-title":"PEGylated antibodies and antibody fragments for improved therapy: a review","volume":"54","author":"Chapman","year":"2002","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"10.1016\/j.xphs.2023.05.014_bib0198","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.addr.2007.05.016","article-title":"PEGylation of cyanovirin-N, an entry inhibitor of HIV","volume":"60","author":"Zappe","year":"2008","journal-title":"Adv Drug Deliv Rev"},{"issue":"6","key":"10.1016\/j.xphs.2023.05.014_bib0199","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1248\/bpb.b13-00059","article-title":"The polyethyleneglycol dilemma: advantage and disadvantage of PEGylation of liposomes for systemic genes and nucleic acids delivery to tumors","volume":"36","author":"Hatakeyama","year":"2013","journal-title":"Biol Pharm Bull"},{"issue":"1","key":"10.1016\/j.xphs.2023.05.014_bib0200","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jconrel.2013.07.026","article-title":"The accelerated blood clearance (ABC) phenomenon: clinical challenge and approaches to manage","volume":"172","author":"Abu Lila","year":"2013","journal-title":"J Control Release"},{"issue":"sup1","key":"10.1016\/j.xphs.2023.05.014_bib0201","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1080\/10717544.2017.1388451","article-title":"Cleavable PEGylation: a strategy for overcoming the \u201cPEG dilemma\u201d in efficient drug delivery","volume":"24","author":"Fang","year":"2017","journal-title":"Drug Deliv"},{"issue":"4","key":"10.1016\/j.xphs.2023.05.014_bib0202","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/jth.12506","article-title":"Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A","volume":"12","author":"Coyle","year":"2014","journal-title":"J Thromb Haemost"},{"issue":"9","key":"10.1016\/j.xphs.2023.05.014_bib0203","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1182\/blood-2015-03-630897","article-title":"Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A","volume":"126","author":"Konkle","year":"2015","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.xphs.2023.05.014_bib0204","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1111\/jth.12161","article-title":"Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A","volume":"11","author":"Tiede","year":"2013","journal-title":"J Thromb Haemost"},{"issue":"4","key":"10.1016\/j.xphs.2023.05.014_bib0205","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1111\/hae.14052","article-title":"Long-term safety and efficacy results from the phase 3b, open-label, multicentre Continuation study of rurioctocog alfa pegol for prophylaxis in previously treated patients with severe haemophilia A","volume":"26","author":"Chowdary","year":"2020","journal-title":"Haemophilia"},{"issue":"6","key":"10.1016\/j.xphs.2023.05.014_bib0206","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1111\/hae.13853","article-title":"BAY 94-9027 prophylaxis is efficacious and well tolerated for up to >5 years with extended dosing intervals: PROTECT VIII extension interim results","volume":"25","author":"Lalezari","year":"2019","journal-title":"Haemophilia"},{"issue":"2","key":"10.1016\/j.xphs.2023.05.014_bib0207","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1160\/TH16-06-0444","article-title":"Clinical evaluation of glycoPEGylated recombinant FVIII: efficacy and safety in severe haemophilia A","volume":"117","author":"Giangrande","year":"2017","journal-title":"Thromb Haemost"},{"issue":"9","key":"10.1016\/j.xphs.2023.05.014_bib0208","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1160\/TH17-03-0166","article-title":"Safety and efficacy of a glycoPEGylated rFVIII (turoctocog alpha pegol, N8-GP) in paediatric patients with severe haemophilia A","volume":"117","author":"Meunier","year":"2017","journal-title":"Thromb Haemost"},{"issue":"1","key":"10.1016\/j.xphs.2023.05.014_bib0209","doi-asserted-by":"crossref","first-page":"3184","DOI":"10.1182\/blood-2021-146126","article-title":"Immunogenicity, efficacy and safety of rurioctocog alfa pegol in previously untreated patients with severe hemophilia a: interim results from an open-label multicenter clinical trial","volume":"138","author":"Sidonio","year":"2021","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.xphs.2023.05.014_bib0210","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1182\/bloodadvances.2022007529","article-title":"The safety and efficacy of N8-GP (turoctocog alfa pegol) in previously untreated pediatric patients with hemophilia A","volume":"7","author":"Male","year":"2023","journal-title":"Blood Adv"},{"issue":"11","key":"10.1016\/j.xphs.2023.05.014_bib0211","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1016\/S0021-9258(17)40292-4","article-title":"Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase","volume":"252","author":"Abuchowski","year":"1977","journal-title":"J Biol Chem"},{"issue":"Pt B","key":"10.1016\/j.xphs.2023.05.014_bib0212","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jconrel.2016.06.040","article-title":"Anti-PEG antibodies in the clinic: current issues and beyond PEGylation","volume":"244","author":"Zhang","year":"2016","journal-title":"J Control Release"},{"issue":"1","key":"10.1016\/j.xphs.2023.05.014_bib0213","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/cncr.22739","article-title":"Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients","volume":"110","author":"Armstrong","year":"2007","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.xphs.2023.05.014_bib0214","doi-asserted-by":"crossref","first-page":"R60","DOI":"10.1186\/ar4497","article-title":"Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout","volume":"16","author":"Lipsky","year":"2014","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"10.1016\/j.xphs.2023.05.014_bib0215","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/ar4500","article-title":"Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients","volume":"16","author":"Hershfield","year":"2014","journal-title":"Arthritis Res Ther"},{"issue":"1\u20132","key":"10.1016\/j.xphs.2023.05.014_bib0216","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ijpharm.2007.11.005","article-title":"Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes","volume":"354","author":"Ishida","year":"2008","journal-title":"Int J Pharm"},{"issue":"1","key":"10.1016\/j.xphs.2023.05.014_bib0217","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jconrel.2006.01.005","article-title":"Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes","volume":"112","author":"Ishida","year":"2006","journal-title":"J Control Release"},{"issue":"3","key":"10.1016\/j.xphs.2023.05.014_bib0218","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1111\/hae.13963","article-title":"PROTECT VIII Kids: BAY 94-9027 (PEGylated Recombinant Factor VIII) safety and efficacy in previously treated children with severe haemophilia A","volume":"26","author":"Santagostino","year":"2020","journal-title":"Haemophilia"},{"issue":"2","key":"10.1016\/j.xphs.2023.05.014_bib0219","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/hae.13119","article-title":"Extended half-life pegylated, full-length recombinant factor VIII for prophylaxis in children with severe haemophilia A","volume":"23","author":"Mullins","year":"2017","journal-title":"Haemophilia"},{"issue":"3","key":"10.1016\/j.xphs.2023.05.014_bib0220","doi-asserted-by":"crossref","first-page":"547","DOI":"10.2165\/00003495-200060030-00003","article-title":"Immune tolerance therapy for haemophilia","volume":"60","author":"Ho","year":"2000","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.xphs.2023.05.014_bib0221","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1182\/blood-2011-08-369132","article-title":"The principal results of the International Immune Tolerance Study: a randomized dose comparison","volume":"119","author":"Hay","year":"2012","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.xphs.2023.05.014_bib0222","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1182\/blood-2014-05-577643","article-title":"Toward optimal therapy for inhibitors in hemophilia","volume":"124","author":"Kempton","year":"2014","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.xphs.2023.05.014_bib0223","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1046\/j.1365-2516.2003.00781.x","article-title":"Immune tolerance induction in patients with haemophilia A with inhibitors: a systematic review","volume":"9","author":"Wight","year":"2003","journal-title":"Haemophilia"},{"issue":"22","key":"10.1016\/j.xphs.2023.05.014_bib0224","doi-asserted-by":"crossref","first-page":"4758","DOI":"10.1182\/blood.V128.22.4758.4758","article-title":"The immune tolerance induction factor utilizations and costs for the management of male hemophilia-a patients who developed inhibitors","volume":"128","author":"Su","year":"2016","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.xphs.2023.05.014_bib0225","doi-asserted-by":"crossref","first-page":"e1331","DOI":"10.1542\/peds.2015-1507","article-title":"Complications of central venous access devices: a systematic review","volume":"136","author":"Ullman","year":"2015","journal-title":"Pediatrics"},{"issue":"5","key":"10.1016\/j.xphs.2023.05.014_bib0226","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/j.1365-2141.2007.06703.x","article-title":"The risk associated with indwelling catheters in children with haemophilia","volume":"138","author":"Ljung","year":"2007","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.xphs.2023.05.014_bib0227","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1111\/hae.14123","article-title":"Emerging benefits of Fc fusion technology in the context of recombinant factor VIII replacement therapy","volume":"26","author":"Meeks","year":"2020","journal-title":"Haemophilia"},{"issue":"5","key":"10.1016\/j.xphs.2023.05.014_bib0228","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nri2762","article-title":"FcgammaRIIB in autoimmunity and infection: evolutionary and therapeutic implications","volume":"10","author":"Smith","year":"2010","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"10.1016\/j.xphs.2023.05.014_bib0229","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/hae.14192","article-title":"Real-world data of immune tolerance induction using recombinant factor VIII Fc fusion protein in patients with severe haemophilia A with inhibitors at high risk for immune tolerance induction failure: a follow-up retrospective analysis","volume":"27","author":"Carcao","year":"2021","journal-title":"Haemophilia"},{"issue":"1","key":"10.1016\/j.xphs.2023.05.014_bib0230","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2516.2008.01931.x","article-title":"Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors","volume":"15","author":"Berntorp","year":"2009","journal-title":"Haemophilia"},{"issue":"2","key":"10.1016\/j.xphs.2023.05.014_bib0231","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1182\/blood-2006-04-017988","article-title":"A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study","volume":"109","author":"Astermark","year":"2007","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.xphs.2023.05.014_bib0232","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/j.1365-2516.2004.00912.x","article-title":"Sequential therapy with activated prothrombin complex concentrate and recombinant factor VIIa in patients with severe haemophilia and inhibitors","volume":"10","author":"Schneiderman","year":"2004","journal-title":"Haemophilia"},{"issue":"2","key":"10.1016\/j.xphs.2023.05.014_bib0233","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/hae.12627","article-title":"Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A","volume":"21","author":"Kruse-Jarres","year":"2015","journal-title":"Haemophilia"},{"issue":"4","key":"10.1016\/j.xphs.2023.05.014_bib0234","first-page":"365","article-title":"Porcine recombinant factor VIII: an additional weapon to handle anti-factor VIII antibodies","volume":"15","author":"Mannucci","year":"2017","journal-title":"Blood Transfus"},{"issue":"8","key":"10.1016\/j.xphs.2023.05.014_bib0235","doi-asserted-by":"crossref","first-page":"e12631","DOI":"10.1002\/rth2.12631","article-title":"Recombinant porcine factor VIII: lessons from the past and place in the management of hemophilia A with inhibitors in 2021","volume":"5","author":"Dargaud","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"issue":"1","key":"10.1016\/j.xphs.2023.05.014_bib0236","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/jth.14618","article-title":"Cross-reacting inhibitors against recombinant porcine factor VIII in acquired hemophilia A: data from the GTH-AH 01\/2010 Study","volume":"18","author":"Turkantoz","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"6","key":"10.1016\/j.xphs.2023.05.014_bib0237","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1111\/hae.14162","article-title":"Cross-reacting recombinant porcine FVIII inhibitors in patients with acquired haemophilia A","volume":"26","author":"Bowyer","year":"2020","journal-title":"Haemophilia"},{"issue":"3","key":"10.1016\/j.xphs.2023.05.014_bib0238","first-page":"223","article-title":"Emicizumab for the treatment of haemophilia A: a narrative review","volume":"17","author":"Franchini","year":"2019","journal-title":"Blood Transfus"},{"issue":"9","key":"10.1016\/j.xphs.2023.05.014_bib0239","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.xphs.2023.05.014_bib0240","doi-asserted-by":"crossref","first-page":"4303","DOI":"10.3390\/jcm10194303","article-title":"Real-world data on bleeding patterns of hemophilia A patients treated with emicizumab","volume":"10","author":"Levy-Mendelovich","year":"2021","journal-title":"J Clin Med"},{"issue":"5","key":"10.1016\/j.xphs.2023.05.014_bib0241","doi-asserted-by":"crossref","first-page":"e12561","DOI":"10.1002\/rth2.12561","article-title":"The effect of emicizumab and bypassing agents in patients with hemophilia - an in vitro study","volume":"5","author":"Schultz","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"issue":"16","key":"10.1016\/j.xphs.2023.05.014_bib0242","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1111\/jth.14203","article-title":"In vitro studies show synergistic effects of a procoagulant bispecific antibody and bypassing agents","author":"Hartmann","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"2","key":"10.1016\/j.xphs.2023.05.014_bib0243","doi-asserted-by":"crossref","first-page":"e94","DOI":"10.1055\/s-0040-1710032","article-title":"Synergistic effect of bypassing agents and sequence identical analogue of emicizumab and fibrin clot structure in the in vitro model of hemophilia A","volume":"4","author":"Zong","year":"2020","journal-title":"TH Open"},{"issue":"3","key":"10.1016\/j.xphs.2023.05.014_bib0244","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/hae.13495","article-title":"Treatment of bleeding episodes in haemophilia A complicated by a factor VIII inhibitor in patients receiving Emicizumab. Interim guidance from UKHCDO Inhibitor Working Party and Executive Committee","volume":"24","author":"Collins","year":"2018","journal-title":"Haemophilia"},{"issue":"3","key":"10.1016\/j.xphs.2023.05.014_bib0245","doi-asserted-by":"crossref","first-page":"e305","DOI":"10.1111\/hae.14010","article-title":"Optimizing the management of patients with haemophilia A and inhibitors in the era of emicizumab: recommendations from a German expert panel","volume":"27","author":"Escuriola-Ettingshausen","year":"2021","journal-title":"Haemophilia"},{"issue":"5","key":"10.1016\/j.xphs.2023.05.014_bib0246","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/hae.13817","volume":"25","author":"Susen","year":"2019","journal-title":"Haemophilia"},{"issue":"2","key":"10.1016\/j.xphs.2023.05.014_bib0247","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s40259-020-00465-4","article-title":"Immunogenicity challenges associated with subcutaneous delivery of therapeutic proteins","volume":"35","author":"Jarvi","year":"2021","journal-title":"BioDrugs"},{"issue":"5","key":"10.1016\/j.xphs.2023.05.014_bib0248","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.xphs.2018.01.007","article-title":"Challenges and opportunities for the subcutaneous delivery of therapeutic proteins","volume":"107","author":"Turner","year":"2018","journal-title":"J Pharm Sci"},{"issue":"4","key":"10.1016\/j.xphs.2023.05.014_bib0249","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1208\/s12248-013-9510-6","article-title":"Immunogenicity of subcutaneously administered therapeutic proteins\u2013a mechanistic perspective","volume":"15","author":"Fathallah","year":"2013","journal-title":"AAPS J"},{"issue":"6","key":"10.1016\/j.xphs.2023.05.014_bib0250","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1111\/hae.14398","article-title":"Low immunogenicity of emicizumab in persons with haemophilia A","volume":"27","author":"Schmitt","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.xphs.2023.05.014_bib0251","series-title":"Humira [Package Insert]","year":"2002"},{"key":"10.1016\/j.xphs.2023.05.014_bib0252","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/ejh.12372","article-title":"Immunosuppressive agents in the treatment of inhibitors in congenital haemophilia A and B\u2013a systematic literature review","volume":"76","author":"Laros-van Gorkom","year":"2014","journal-title":"Eur J Haematol Suppl"},{"issue":"5","key":"10.1016\/j.xphs.2023.05.014_bib0253","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1055\/s-0038-1649664","article-title":"A prospective, randomized trial of prednisone and cyclophosphamide in the treatment of patients with factor VIII autoantibodies","volume":"70","author":"Green","year":"1993","journal-title":"Thromb Haemost"},{"issue":"1","key":"10.1016\/j.xphs.2023.05.014_bib0254","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1182\/blood-2012-02-409185","article-title":"Immunosuppression for acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2)","volume":"120","author":"Collins","year":"2012","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.xphs.2023.05.014_bib0255","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1046\/j.1365-2141.2003.04162.x","article-title":"Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors","volume":"121","author":"Delgado","year":"2003","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.xphs.2023.05.014_bib0256","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/hematology.2019000007","article-title":"Gene therapy for hemophilia","volume":"2019","author":"Nathwani","year":"2019","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"6","key":"10.1016\/j.xphs.2023.05.014_bib0257","doi-asserted-by":"crossref","first-page":"e12586","DOI":"10.1002\/rth2.12586","article-title":"The intersection of vector biology, gene therapy, and hemophilia","volume":"5","author":"Lisowski","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.xphs.2023.05.014_bib0258","doi-asserted-by":"crossref","first-page":"618","DOI":"10.3389\/fimmu.2020.00618","article-title":"Translational potential of immune tolerance induction by AAV liver-directed factor VIII gene therapy for hemophilia A","volume":"11","author":"Samelson-Jones","year":"2020","journal-title":"Front Immunol"},{"issue":"6563","key":"10.1016\/j.xphs.2023.05.014_bib0259","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1126\/science.abg0856","article-title":"Hemophilia as a blueprint for gene therapy","volume":"374","author":"Ragni","year":"2021","journal-title":"Science"},{"issue":"21","key":"10.1016\/j.xphs.2023.05.014_bib0260","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1056\/NEJMoa2104205","article-title":"Multiyear factor VIII expression after AAV gene transfer for hemophilia A","volume":"385","author":"George","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.xphs.2023.05.014_bib0261","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa1908490","article-title":"Multiyear follow-up of AAV5-hFVIII-SQ gene therapy for hemophilia A","volume":"382","author":"Pasi","year":"2020","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.xphs.2023.05.014_bib0262","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nm1358","article-title":"Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response","volume":"12","author":"Manno","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.xphs.2023.05.014_bib0263","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.omtm.2022.07.018","article-title":"Immunogenicity assessment of AAV-based gene therapies: an IQ consortium industry white paper","volume":"26","author":"Yang","year":"2022","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"9","key":"10.1016\/j.xphs.2023.05.014_bib0264","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/j.ymthe.2020.06.001","article-title":"Long-term follow-up of the first in human intravascular delivery of AAV for gene transfer: aAV2-hFIX16 for severe hemophilia B","volume":"28","author":"George","year":"2020","journal-title":"Mol Ther"},{"issue":"2","key":"10.1016\/j.xphs.2023.05.014_bib0265","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.ymthe.2020.12.008","article-title":"Early phase clinical immunogenicity of valoctocogene roxaparvovec, an AAV5-mediated gene therapy for hemophilia A","volume":"29","author":"Long","year":"2021","journal-title":"Mol Ther"},{"issue":"26","key":"10.1016\/j.xphs.2023.05.014_bib0266","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMoa1708483","article-title":"AAV5-factor VIII gene transfer in severe hemophilia A","volume":"377","author":"Rangarajan","year":"2017","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.xphs.2023.05.014_bib0267","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","article-title":"Adenovirus-associated virus vector-mediated gene transfer in hemophilia B","volume":"365","author":"Nathwani","year":"2011","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.xphs.2023.05.014_bib0268","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1002\/lt.20519","article-title":"Changes in liver volume from birth to adulthood: a meta-analysis","volume":"11","author":"Johnson","year":"2005","journal-title":"Liver Transpl"},{"issue":"493","key":"10.1016\/j.xphs.2023.05.014_bib0269","doi-asserted-by":"crossref","first-page":"eaav7325","DOI":"10.1126\/scitranslmed.aav7325","article-title":"Phagocytosis-shielded lentiviral vectors improve liver gene therapy in nonhuman primates","volume":"11","author":"Milani","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.xphs.2023.05.014_bib0270","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.omtm.2018.01.011","article-title":"Platelet-targeted gene therapy for hemophilia","volume":"9","author":"Shi","year":"2018","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"11","key":"10.1016\/j.xphs.2023.05.014_bib0271","doi-asserted-by":"crossref","first-page":"e264","DOI":"10.1038\/mtna.2015.37","article-title":"Off-target effects in CRISPR\/Cas9-mediated genome engineering","volume":"4","author":"Zhang","year":"2015","journal-title":"Mol Ther Nucleic Acids"},{"issue":"1","key":"10.1016\/j.xphs.2023.05.014_bib0272","doi-asserted-by":"crossref","first-page":"16838","DOI":"10.1038\/s41598-019-53198-y","article-title":"Hemophilia A ameliorated in mice by CRISPR-based in vivo genome editing of human factor VIII","volume":"9","author":"Chen","year":"2019","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.xphs.2023.05.014_bib0273","doi-asserted-by":"crossref","first-page":"eabj6901","DOI":"10.1126\/sciadv.abj6901","article-title":"In vivo delivery of CRISPR-Cas9 using lipid nanoparticles enables antithrombin gene editing for sustainable hemophilia A and B therapy","volume":"8","author":"Han","year":"2022","journal-title":"Sci Adv"},{"key":"10.1016\/j.xphs.2023.05.014_bib0274","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.672564","article-title":"CRISPR\/Cas9-mediated in vivo genetic correction in a mouse model of hemophilia A","volume":"9","author":"Luo","year":"2021","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"10.1016\/j.xphs.2023.05.014_bib0275","doi-asserted-by":"crossref","first-page":"3497","DOI":"10.1038\/s41467-018-05843-9","article-title":"Cas9 immunity creates challenges for CRISPR gene editing therapies","volume":"9","author":"Crudele","year":"2018","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.xphs.2023.05.014_bib0276","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.xphs.2019.10.003","article-title":"Immunogenicity of Cas9 protein","volume":"109","author":"Mehta","year":"2020","journal-title":"J Pharm Sci"},{"issue":"10","key":"10.1016\/j.xphs.2023.05.014_bib0277","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/nmeth.3993","article-title":"A multifunctional AAV-CRISPR-Cas9 and its host response","volume":"13","author":"Chew","year":"2016","journal-title":"Nat Methods"},{"issue":"7","key":"10.1016\/j.xphs.2023.05.014_bib0278","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1089\/hum.2015.087","article-title":"Adenovirus-mediated somatic genome editing of Pten by CRISPR\/Cas9 in mouse liver in spite of Cas9-specific immune responses","volume":"26","author":"Wang","year":"2015","journal-title":"Hum Gene Ther"},{"issue":"2","key":"10.1016\/j.xphs.2023.05.014_bib0279","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/s41591-018-0326-x","article-title":"Identification of preexisting adaptive immunity to Cas9 proteins in humans","volume":"25","author":"Charlesworth","year":"2019","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.xphs.2023.05.014_bib0280","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/s41591-018-0204-6","article-title":"High prevalence of Streptococcus pyogenes Cas9-reactive T cells within the adult human population","volume":"25","author":"Wagner","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.xphs.2023.05.014_bib0281","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.omtm.2018.06.006","article-title":"Prevalence of pre-existing antibodies to CRISPR-associated nuclease Cas9 in the USA population","volume":"10","author":"Simhadri","year":"2018","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"1","key":"10.1016\/j.xphs.2023.05.014_bib0282","doi-asserted-by":"crossref","first-page":"5090","DOI":"10.1038\/s41467-021-25414-9","article-title":"Cas9-derived peptides presented by MHC Class II that elicit proliferation of CD4(+) T-cells","volume":"12","author":"Simhadri","year":"2021","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.xphs.2023.05.014_bib0283","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/j.ymthe.2020.04.017","article-title":"AAV-CRISPR gene editing is negated by pre-existing immunity to Cas9","volume":"28","author":"Li","year":"2020","journal-title":"Mol Ther"},{"issue":"8","key":"10.1016\/j.xphs.2023.05.014_bib0284","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/nrg3763","article-title":"Non-viral vectors for gene-based therapy","volume":"15","author":"Yin","year":"2014","journal-title":"Nat Rev Genet"},{"issue":"1","key":"10.1016\/j.xphs.2023.05.014_bib0285","first-page":"GE01","article-title":"Non viral vectors in gene therapy- an overview","volume":"9","author":"Ramamoorth","year":"2015","journal-title":"J Clin Diagn Res"},{"key":"10.1016\/j.xphs.2023.05.014_bib0286","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2014.04.003","article-title":"B cell-intrinsic toll-like receptor 7 is responsible for the enhanced anti-PEG IgM production following injection of siRNA-containing PEGylated lipoplex in mice","volume":"184","author":"Hashimoto","year":"2014","journal-title":"J Control Release"},{"issue":"6","key":"10.1016\/j.xphs.2023.05.014_bib0287","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/gt.2014.32","article-title":"Activation of TLR9 by incorporated pDNA within PEG-coated lipoplex enhances anti-PEG IgM production","volume":"21","author":"Hashimoto","year":"2014","journal-title":"Gene Ther"},{"key":"10.1016\/j.xphs.2023.05.014_bib0288","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120529","article-title":"Nucleic acids delivered by PEGylated cationic liposomes in systemic lupus erythematosus-prone mice: a possible exacerbation of lupus nephritis in the presence of pre-existing anti-nucleic acid antibodies","volume":"601","author":"Takata","year":"2021","journal-title":"Int J Pharm"},{"issue":"1","key":"10.1016\/j.xphs.2023.05.014_bib0289","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1186\/s12951-022-01478-7","article-title":"Recent advances in mRNA-LNP therapeutics: immunological and pharmacological aspects","volume":"20","author":"Kiaie","year":"2022","journal-title":"J Nanobiotechnol"},{"issue":"6","key":"10.1016\/j.xphs.2023.05.014_bib0290","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/cdd.2016.11","article-title":"Phosphatidylserine is a global immunosuppressive signal in efferocytosis, infectious disease, and cancer","volume":"23","author":"Birge","year":"2016","journal-title":"Cell Death Differ"},{"issue":"7","key":"10.1016\/j.xphs.2023.05.014_bib0291","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/sj.cdd.4400404","article-title":"The role of phosphatidylserine in recognition of apoptotic cells by phagocytes","volume":"5","author":"Fadok","year":"1998","journal-title":"Cell Death Differ"},{"issue":"8","key":"10.1016\/j.xphs.2023.05.014_bib0292","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1016\/j.xphs.2018.03.027","article-title":"Phosphatidylserine is not just a cleanup crew but also a well-meaning teacher","volume":"107","author":"Glassman","year":"2018","journal-title":"J Pharm Sci"},{"issue":"24","key":"10.1016\/j.xphs.2023.05.014_bib0293","doi-asserted-by":"crossref","first-page":"17051","DOI":"10.1074\/jbc.C112.396325","article-title":"Exposure to factor VIII protein in the presence of phosphatidylserine induces hypo-responsiveness toward factor VIII challenge in hemophilia A mice","volume":"288","author":"Gaitonde","year":"2013","journal-title":"J Biol Chem"},{"issue":"10","key":"10.1016\/j.xphs.2023.05.014_bib0294","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1016\/j.xphs.2016.06.018","article-title":"Phosphatidylserine converts immunogenic recombinant human acid alpha-glucosidase to a tolerogenic form in a mouse model of pompe disease","volume":"105","author":"Schneider","year":"2016","journal-title":"J Pharm Sci"},{"issue":"10","key":"10.1016\/j.xphs.2023.05.014_bib0295","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1016\/j.xphs.2016.06.008","article-title":"Effect of biophysical properties of phosphatidylserine particle on immune tolerance induction toward factor VIII in a hemophilia A mouse model","volume":"105","author":"Ramakrishnan","year":"2016","journal-title":"J Pharm Sci"},{"issue":"8","key":"10.1016\/j.xphs.2023.05.014_bib0296","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1002\/jps.24513","article-title":"Exposure of FVIII in the presence of phosphatidyl serine reduces generation of memory B-cells and induces regulatory T-cell-mediated hyporesponsiveness in hemophilia A mice","volume":"104","author":"Ramakrishnan","year":"2015","journal-title":"J Pharm Sci"},{"issue":"2","key":"10.1016\/j.xphs.2023.05.014_bib0297","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.clim.2010.10.006","article-title":"Phosphatidylserine reduces immune response against human recombinant Factor VIII in hemophilia A mice by regulation of dendritic cell function","volume":"138","author":"Gaitonde","year":"2011","journal-title":"Clin Immunol"},{"issue":"1","key":"10.1016\/j.xphs.2023.05.014_bib0298","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.ijpharm.2018.07.018","article-title":"Subcutaneous administration of Lyso-phosphatidylserine nanoparticles induces immunological tolerance towards Factor VIII in a Hemophilia A mouse model","volume":"548","author":"Glassman","year":"2018","journal-title":"Int J Pharm"},{"issue":"1","key":"10.1016\/j.xphs.2023.05.014_bib0299","doi-asserted-by":"crossref","first-page":"17853","DOI":"10.1038\/s41598-021-97333-0","article-title":"Rational design of a nanoparticle platform for oral prophylactic immunotherapy to prevent immunogenicity of therapeutic proteins","volume":"11","author":"Nguyen","year":"2021","journal-title":"Sci Rep"},{"issue":"11","key":"10.1016\/j.xphs.2023.05.014_bib0300","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1111\/jth.15497","article-title":"Tolerogenic form of factor VIII to prevent inhibitor development in the treatment of hemophilia A","volume":"19","author":"Nguyen","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"7","key":"10.1016\/j.xphs.2023.05.014_bib0301","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1016\/j.xphs.2022.01.025","article-title":"Biophysical characterization of tolerogenic lipid-based nanoparticles containing phosphatidylcholine and lysophosphatidylserine","volume":"111","author":"Nguyen","year":"2022","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2023.05.014_bib0302","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2022.104660","article-title":"Phosphatidylserine-mediated oral tolerance","volume":"384","author":"Nguyen","year":"2023","journal-title":"Cell Immunol"},{"key":"10.1016\/j.xphs.2023.05.014_bib0303","doi-asserted-by":"crossref","first-page":"969","DOI":"10.3389\/fimmu.2020.00969","article-title":"Development of ImmTOR tolerogenic nanoparticles for the mitigation of anti-drug antibodies","volume":"11","author":"Kishimoto","year":"2020","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.xphs.2023.05.014_bib0304","doi-asserted-by":"crossref","first-page":"E156","DOI":"10.1073\/pnas.1408686111","article-title":"Polymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance","volume":"112","author":"Maldonado","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.xphs.2023.05.014_bib0305","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.cellimm.2015.11.004","article-title":"Tolerogenic nanoparticles to induce immunologic tolerance: prevention and reversal of FVIII inhibitor formation","volume":"301","author":"Zhang","year":"2016","journal-title":"Cell Immunol"},{"issue":"2","key":"10.1016\/j.xphs.2023.05.014_bib0306","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1136\/annrheumdis-2017-eular.3548","article-title":"THU0422 SEL-212: enhanced serum uric acid control in hyperuricemic patients through selective mitigation of anti-drug antibodies against pegsiticase","volume":"76","author":"Sands","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.xphs.2023.05.014_bib0307","unstructured":"Sands E., Kivitz A.J., DeHaan P.D.W., Johnston L., Kishimoto T.K. Update of SEL-212 phase 2 clinical data in symptomatic gout patients: Svp-Rapamycin combined with pegadricase mitigates immunogenicity and enables sustained reduction of serum uric acid levels, low rate of gout flares and monthly dosing [Abstract]. 2018 (70 (suppl 10))."},{"issue":"1","key":"10.1016\/j.xphs.2023.05.014_bib0308","doi-asserted-by":"crossref","first-page":"E60","DOI":"10.1073\/pnas.1216353110","article-title":"Engineering antigens for in situ erythrocyte binding induces T-cell deletion","volume":"110","author":"Kontos","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.xphs.2023.05.014_bib0309","doi-asserted-by":"crossref","first-page":"15907","DOI":"10.1038\/srep15907","article-title":"Memory of tolerance and induction of regulatory T cells by erythrocyte-targeted antigens","volume":"5","author":"Grimm","year":"2015","journal-title":"Sci Rep"},{"issue":"56","key":"10.1016\/j.xphs.2023.05.014_bib0310","doi-asserted-by":"crossref","first-page":"eabe1801","DOI":"10.1126\/sciimmunol.abe1801","article-title":"Persistent antigen exposure via the eryptotic pathway drives terminal T cell dysfunction","volume":"6","author":"Watkins","year":"2021","journal-title":"Sci Immunol"},{"issue":"7","key":"10.1016\/j.xphs.2023.05.014_bib0311","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.it.2015.05.007","article-title":"Harnessing nanoparticles for immune modulation","volume":"36","author":"Getts","year":"2015","journal-title":"Trends Immunol"},{"issue":"18","key":"10.1016\/j.xphs.2023.05.014_bib0312","doi-asserted-by":"crossref","first-page":"5059","DOI":"10.1073\/pnas.1505782113","article-title":"Biodegradable antigen-associated PLG nanoparticles tolerize Th2-mediated allergic airway inflammation pre- and postsensitization","volume":"113","author":"Smarr","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"10.1016\/j.xphs.2023.05.014_bib0313","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/j.ymthe.2017.04.015","article-title":"Controlled delivery of single or multiple antigens in tolerogenic nanoparticles using peptide-polymer bioconjugates","volume":"25","author":"Pearson","year":"2017","journal-title":"Mol Ther"},{"issue":"6","key":"10.1016\/j.xphs.2023.05.014_bib0314","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1053\/j.gastro.2020.01.045","article-title":"Gliadin nanoparticles induce immune tolerance to gliadin in mouse models of celiac disease","volume":"158","author":"Freitag","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.xphs.2023.05.014_bib0315","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.biomaterials.2015.10.041","article-title":"Tolerance induction using nanoparticles bearing HY peptides in bone marrow transplantation","volume":"76","author":"Hlavaty","year":"2016","journal-title":"Biomaterials"},{"key":"10.1016\/j.xphs.2023.05.014_bib0316","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jaut.2017.12.010","article-title":"Tolerogenic Ag-PLG nanoparticles induce tregs to suppress activated diabetogenic CD4 and CD8 T cells","volume":"89","author":"Prasad","year":"2018","journal-title":"J Autoimmun"},{"issue":"7","key":"10.1016\/j.xphs.2023.05.014_bib0317","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1016\/j.ymthe.2017.03.032","article-title":"Peptide-conjugated nanoparticles reduce positive co-stimulatory expression and T cell activity to induce tolerance","volume":"25","author":"Kuo","year":"2017","journal-title":"Mol Ther"},{"issue":"5","key":"10.1016\/j.xphs.2023.05.014_bib0318","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.4049\/jimmunol.1004175","article-title":"Tolerance induced by apoptotic antigen-coupled leukocytes is induced by PD-L1+ and IL-10-producing splenic macrophages and maintained by T regulatory cells","volume":"187","author":"Getts","year":"2011","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.xphs.2023.05.014_bib0319","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1053\/j.gastro.2021.03.014","article-title":"TAK-101 nanoparticles induce gluten-specific tolerance in celiac disease: a randomized, double-blind, placebo-controlled study","volume":"161","author":"Kelly","year":"2021","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.xphs.2023.05.014_bib0320","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.bbmt.2013.06.004","article-title":"Adoptive transfer of umbilical cord blood-derived regulatory T cells and early viral reactivation","volume":"19","author":"Brunstein","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.xphs.2023.05.014_bib0321","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/jth.14659","article-title":"Antigen-specific in vitro expansion of factor VIII-specific regulatory T cells induces tolerance in hemophilia A mice","volume":"18","author":"Smith","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.xphs.2023.05.014_bib0322","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.omtm.2019.11.022","article-title":"Genetic engineering of T cells for immune tolerance","volume":"16","author":"Scott","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"7","key":"10.1016\/j.xphs.2023.05.014_bib0323","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1182\/blood-2014-04-566786","article-title":"Engineered antigen-specific human regulatory T cells: immunosuppression of FVIII-specific T- and B-cell responses","volume":"125","author":"Kim","year":"2015","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.xphs.2023.05.014_bib0324","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1182\/blood-2016-07-727834","article-title":"FVIII-specific human chimeric antigen receptor T-regulatory cells suppress T- and B-cell responses to FVIII","volume":"129","author":"Yoon","year":"2017","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.xphs.2023.05.014_bib0325","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/j.1365-2516.2004.00904.x","article-title":"Inhibitor development in patients receiving recombinant factor VIII (Recombinate rAHF\/Bioclate): a prospective pharmacovigilance study","volume":"10","author":"Ewenstein","year":"2004","journal-title":"Haemophilia"},{"issue":"9","key":"10.1016\/j.xphs.2023.05.014_bib0326","first-page":"2428","article-title":"A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group","volume":"83","author":"Bray","year":"1994","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.xphs.2023.05.014_bib0327","first-page":"779","article-title":"French previously untreated patients with severe hemophilia A after exposure to recombinant factor VIII : incidence of inhibitor and evaluation of immune tolerance","volume":"80","author":"Rothschild","year":"1998","journal-title":"Thromb Haemost"},{"issue":"6","key":"10.1016\/j.xphs.2023.05.014_bib0328","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1055\/s-0037-1613925","article-title":"Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy\u2013International Kogenate-FS Study Group","volume":"83","author":"Abshire","year":"2000","journal-title":"Thromb Haemost"},{"issue":"4","key":"10.1016\/j.xphs.2023.05.014_bib0329","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/j.1365-2516.2007.01472.x","article-title":"Safety and efficacy of a sucrose-formulated recombinant factor VIII product for the treatment of previously treated patients with haemophilia A in China","volume":"13","author":"Shi","year":"2007","journal-title":"Haemophilia"},{"issue":"3","key":"10.1016\/j.xphs.2023.05.014_bib0330","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1160\/TH03-10-0643","article-title":"Full-length sucrose-formulated recombinant factor VIII for treatment of previously untreated or minimally treated young children with severe haemophilia A: results of an international clinical investigation","volume":"93","author":"Kreuz","year":"2005","journal-title":"Thromb Haemost"},{"issue":"5","key":"10.1016\/j.xphs.2023.05.014_bib0331","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1365-2516.2004.00932.x","article-title":"Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma\/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A","volume":"10","author":"Tarantino","year":"2004","journal-title":"Haemophilia"},{"issue":"6","key":"10.1016\/j.xphs.2023.05.014_bib0332","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1160\/TH11-09-0642","article-title":"Experience of Advate rAHF-PFM in previously untreated patients and minimally treated patients with haemophilia A","volume":"107","author":"Auerswald","year":"2012","journal-title":"Thromb Haemost"},{"issue":"1","key":"10.1016\/j.xphs.2023.05.014_bib0333","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/bjh.15728","article-title":"on the behalf of the HSG. Inhibitor incidence in haemophilia A under exclusive use of a third-generation recombinant factor VIII concentrate: results of the HEMFIL cohort study","volume":"186","author":"Jardim","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.xphs.2023.05.014_bib0334","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.thromres.2020.03.005","article-title":"Continued benefit demonstrated with BAY 81-8973 prophylaxis in previously treated children with severe haemophilia A: interim analysis from the LEOPOLD Kids extension study","volume":"189","author":"Kenet","year":"2020","journal-title":"Thromb Res"},{"issue":"4","key":"10.1016\/j.xphs.2023.05.014_bib0335","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/j.1365-2516.2009.02027.x","volume":"15","author":"Recht","year":"2009","journal-title":"Haemophilia"},{"issue":"6","key":"10.1016\/j.xphs.2023.05.014_bib0336","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1111\/hae.13551","article-title":"The immunogenicity of ReFacto AF (moroctocog alfa AF-CC) in previously untreated patients with haemophilia A in the United Kingdom","volume":"24","author":"Mathias","year":"2018","journal-title":"Haemophilia"},{"issue":"5","key":"10.1016\/j.xphs.2023.05.014_bib0337","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1111\/hae.12165","article-title":"Results from a large multinational clinical trial (guardian\u21223) using prophylactic treatment with turoctocog alfa in paediatric patients with severe haemophilia A: safety, efficacy and pharmacokinetics","volume":"19","author":"Kulkarni","year":"2013","journal-title":"Haemophilia"},{"issue":"1","key":"10.1016\/j.xphs.2023.05.014_bib0338","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/hae.13883","article-title":"Safety and efficacy of turoctocog alfa in the prevention and treatment of bleeds in previously untreated paediatric patients with severe haemophilia A: results from the guardian 4 multinational clinical trial","volume":"26","author":"Yaish","year":"2020","journal-title":"Haemophilia"},{"issue":"5","key":"10.1016\/j.xphs.2023.05.014_bib0339","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1182\/blood-2016-01-687434","article-title":"Efficacy and safety of rVIII-SingleChain: results of a phase 1\/3 multicenter clinical trial in severe hemophilia A","volume":"128","author":"Mahlangu","year":"2016","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.xphs.2023.05.014_bib0340","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/jth.13647","article-title":"Safety, efficacy and pharmacokinetics of rVIII-SingleChain in children with severe hemophilia A: results of a multicenter clinical trial","volume":"15","author":"Stasyshyn","year":"2017","journal-title":"J Thromb Haemost"},{"issue":"13","key":"10.1016\/j.xphs.2023.05.014_bib0341","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1182\/blood.2020005673","article-title":"Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study","volume":"137","author":"Klamroth","year":"2021","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.xphs.2023.05.014_bib0342","first-page":"229","article-title":"Efficacy and safety of a monoclonal purified factor VIII concentrate: 5-year follow-up in previously treated HIV-negative haemophiliacs","volume":"25","author":"Smid","year":"1995","journal-title":"Haemostasis"},{"issue":"3","key":"10.1016\/j.xphs.2023.05.014_bib0343","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/BF01703244","article-title":"Viral safety and inhibitor development associated with monoclonal antibody-purified F VIII C","volume":"63","author":"Lusher","year":"1991","journal-title":"Ann Hematol"},{"issue":"22","key":"10.1016\/j.xphs.2023.05.014_bib0344","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1182\/blood.V114.22.3141.3141","article-title":"Absence of inhibitor development in the routine clinical use of alphanate\u00ae in patients with severe hemophilia A: results from a long-term post-marketing surveillance study","volume":"114","author":"Sexauer","year":"2009","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.xphs.2023.05.014_bib0345","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1111\/trf.14241","article-title":"Safety of a pasteurized plasma-derived Factor VIII and von Willebrand factor concentrate: analysis of 33 years of pharmacovigilance data","volume":"57","author":"Kouides","year":"2017","journal-title":"Transfusion"},{"key":"10.1016\/j.xphs.2023.05.014_bib0346","doi-asserted-by":"crossref","DOI":"10.1177\/2040620720914692","article-title":"octanate((R)): over 20 years of clinical experience in overcoming challenges in haemophilia A treatment","volume":"11","author":"Klukowska","year":"2020","journal-title":"Ther Adv Hematol"},{"issue":"2","key":"10.1016\/j.xphs.2023.05.014_bib0347","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/hae.13385","article-title":"Low incidence of factor VIII inhibitors in previously untreated patients with severe haemophilia A treated with octanate((R)) : final report from a prospective study","volume":"24","author":"Klukowska","year":"2018","journal-title":"Haemophilia"},{"issue":"3","key":"10.1016\/j.xphs.2023.05.014_bib0348","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.thromres.2010.11.030","article-title":"Clinical efficacy of a novel VWF-containing FVIII concentrate, Wilate((R)), in the prophylaxis and treatment of bleeding episodes in previously treated haemophilia A patients","volume":"127","author":"Klukowska","year":"2011","journal-title":"Thromb Res"},{"issue":"6","key":"10.1016\/j.xphs.2023.05.014_bib0349","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/hae.12479","article-title":"Incidence and risk factors for inhibitor development in previously untreated severe haemophilia A patients born between 2005 and 2010","volume":"20","author":"Vezina","year":"2014","journal-title":"Haemophilia"},{"issue":"S2","key":"10.1016\/j.xphs.2023.05.014_bib0350","first-page":"129","article-title":"SPK-8016: preliminary results from a phase 1\/2 clinical trial of gene therapy for hemophilia A. Special issue: virtual congress of the European Association for Haemophilia and Allied Disorders","volume":"27","author":"Sullivan","year":"2021","journal-title":"Haemophilia"},{"issue":"11","key":"10.1016\/j.xphs.2023.05.014_bib0351","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1056\/NEJMoa2113708","article-title":"Valoctocogene roxaparvovec gene therapy for hemophilia A","volume":"386","author":"Ozelo","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.xphs.2023.05.014_bib0352","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1182\/blood-2020-137648","article-title":"Updated follow-up of the alta study, a phase 1\/2 study of giroctocogene fitelparvovec (SB-525) gene therapy in adults with severe hemophilia A","volume":"136","author":"Leavitt","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.xphs.2023.05.014_bib0353","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1182\/blood-2020-139803","article-title":"First-in-human gene therapy study of AAVhu37 capsid vector technology in severe hemophilia A - BAY 2599023 has broad patient eligibility and stable and sustained long-term expression of FVIII","volume":"136","author":"Pipe","year":"2020","journal-title":"Blood"},{"issue":"S2","key":"10.1016\/j.xphs.2023.05.014_bib0354","first-page":"122","volume":"27","author":"Chaplin","year":"2021","journal-title":"Haemophilia"},{"issue":"21","key":"10.1016\/j.xphs.2023.05.014_bib0355","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","article-title":"Long-term safety and efficacy of factor IX gene therapy in hemophilia B","volume":"371","author":"Nathwani","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.xphs.2023.05.014_bib0356","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood-2020-139225","article-title":"AMT-060 gene therapy in adults with severe or moderate-severe hemophilia B confirm stable FIX expression and durable reductions in bleeding and factor IX consumption for up to 5 years","volume":"136","author":"Leebeek","year":"2020","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.xphs.2023.05.014_bib0357","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1182\/blood-2017-09-804419","article-title":"Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B","volume":"131","author":"Miesbach","year":"2018","journal-title":"Blood"},{"issue":"Supplement_2","key":"10.1016\/j.xphs.2023.05.014_bib0358","doi-asserted-by":"crossref","first-page":"LBA","DOI":"10.1182\/blood-2020-143560","volume":"136","author":"Pipe","year":"2020","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.xphs.2023.05.014_bib0359","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1182\/bloodadvances.2019000811","article-title":"Etranacogene dezaparvovec (AMT-061 phase 2b): normal\/near normal FIX activity and bleed cessation in hemophilia B","volume":"3","author":"Von Drygalski","year":"2019","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.xphs.2023.05.014_bib0360","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1056\/NEJMoa2119913","article-title":"Phase 1-2 trial of AAVS3 gene therapy in patients with hemophilia B","volume":"387","author":"Chowdary","year":"2022","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.xphs.2023.05.014_bib0361","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1182\/blood.2019004625","article-title":"BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression","volume":"137","author":"Konkle","year":"2021","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.xphs.2023.05.014_bib0362","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1089\/hum.2014.106","article-title":"Employing a gain-of-function factor IX variant R338L to advance the efficacy and safety of hemophilia B human gene therapy: preclinical evaluation supporting an ongoing adeno-associated virus clinical trial","volume":"26","author":"Monahan","year":"2015","journal-title":"Hum Gene Ther"},{"issue":"1","key":"10.1016\/j.xphs.2023.05.014_bib0363","first-page":"3331","article-title":"101HEMB01 is a phase 1\/2 open-label, single ascending dose-finding trial of DTX101 (AAVrh10FIX) in patients with moderate\/severe hemophilia B that demonstrated meaningful but transient expression of human factor IX (hFIX)","volume":"130","author":"Pipe","year":"2017","journal-title":"Blood"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354923002010?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354923002010?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T09:45:15Z","timestamp":1758361515000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354923002010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":363,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S0022354923002010"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2023.05.014","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity of Therapeutic Biological Modalities - Lessons from Hemophilia A Therapies","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2023.05.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 American Pharmacists Association. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}